var title_f5_60_6080="Infectious colitis Endosc";
var content_f5_60_6080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infectious colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy of infectious colitis can look identical to either Crohn's disease or ulcerative colitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6080=[""].join("\n");
var outline_f5_60_6080=null;
var title_f5_60_6081="Choanal atresia";
var content_f5_60_6081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F73593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F73593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of choanal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 530px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image A shows bilateral choanal atresia. The bony atresia plate is seen (black arrows), as well as retained secretions in the posterior nasal cavity (red arrow). Image B shows normal anatomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marilene B Wang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6081=[""].join("\n");
var outline_f5_60_6081=null;
var title_f5_60_6082="Heller myotomy performed laparoscopically";
var content_f5_60_6082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heller myotomy performed laparoscopically",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an intraoperative photograph of the laparoscopic performance of the myotomy on the esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6082=[""].join("\n");
var outline_f5_60_6082=null;
var title_f5_60_6083="Diabetes mellitus type 2: Alcohol, exercise, and medical care";
var content_f5_60_6083=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/60/6083/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6083/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/60/6083/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6083/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/60/6083/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6083/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?5/60/6083?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      TYPE 2 DIABETES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Diabetes mellitus is a chronic condition, but people with diabetes can lead a full life while keeping their diabetes under control. Lifestyle modifications (changes in day-to-day habits) are an essential component of any diabetes management plan.",
"    </p>",
"    <p>",
"     Lifestyle modifications can be a very effective way to keep diabetes in control. Improved blood sugar control can slow the progression of long-term complications. Multiple small changes can lead to improvements in diabetes control, including a decreased need for medication.",
"    </p>",
"    <p>",
"     Diabetes requires a lifelong management plan, and persons with diabetes have a central role in this plan. Lifestyle modifications are an opportunity for diabetics to take charge of their health. Therefore, it is important to learn as much as possible about diabetes and to take an active role in making decisions about healthcare and treatment.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ALCOHOL AND TYPE 2 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Drinking a moderate amount of alcohol (up to one serving per day for women, up to two servings per day for men) with food does not affect blood sugar levels significantly. People who take oral diabetes medications do not usually need to adjust their medication, as long as the alcohol is consumed in moderation and with food. Alcohol may cause a slight rise in blood sugar, followed hours later by a decrease in the blood sugar level.",
"    </p>",
"    <p>",
"     Mixers, such as fruit juice or regular cola, can increase blood sugar levels and increase the number of calories consumed in a day. Also, calories from alcohol have little nutritional value and may interfere with efforts to lose weight or contribute to weight gain.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      EXERCISE AND TYPE 2 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Exercise is beneficial for all individuals, with or without diabetes. Even people with longstanding diabetes or diabetic complications can benefit from exercise.",
"    </p>",
"    <p>",
"     For diabetics, exercise promotes cardiovascular fitness and weight loss, lowers high blood pressure, improves lipid profiles, improves blood sugar control in some cases, and leads to an overall sense of well-being. When combined with dietary lifestyle intervention it will even help prevent type 2 diabetes in some people.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      General exercise precautions",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is important to balance enthusiasm and common sense when beginning an exercise program. These precautions encourage patients to stay safe and ensure that exercise is productive.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Wear well-fitting, protective footwear. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"        \"Patient information: Foot care in diabetes mellitus (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Drink adequate liquids before, during, and after exercise to prevent dehydration, which can upset blood sugar levels.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Diabetics who use insulin should also:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Measure blood sugar before, during, and after exercise to determine their body's typical response to exercise. If the pre-exercise blood sugar reading is 250",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (13.9",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       or higher, exercise should be postponed until the level is under control.",
"      </li>",
"      <li>",
"       Consider a decrease in insulin dose by about 30 percent during exercise.",
"      </li>",
"      <li>",
"       Choose an insulin injection site away from exercising muscles (for example, avoid the legs if running).",
"      </li>",
"      <li>",
"       Keep rapidly absorbed carbohydrates on hand (glucose tablets, hard candies, or juice).",
"      </li>",
"      <li>",
"       Eat a snack 15 to 30 minutes before exercise, and again every 30 minutes during exercise.",
"      </li>",
"      <li>",
"       Eat a source of slowly absorbed carbohydrates (dried fruit, fruit jerky, granola bars, or trail mix) immediately after exercise. This will counter a post-exercise drop in blood sugar levels.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      The pre-exercise examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with diabetes who want to start an exercise program should consult with their healthcare provider first. We typically perform a physical examination and a resting electrocardiogram (ECG) in sedentary adults (age &gt;50 years) with diabetes prior to beginning an exercise program. It is best to begin a gentle exercise program and to gradually progress to a more vigorous program as tolerated.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Type of exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gentle aerobic exercises, which increase the heart rate for a sustained period of time, are often the best choice for diabetics. Examples of aerobic exercise include walking, cycling, swimming, or rowing. Diabetics with well-controlled blood sugar levels and no complications can usually participate in most any type of exercise.",
"    </p>",
"    <p>",
"     Choose exercise that is enjoyable and can be performed comfortably, making it easier to stay motivated and stick with a program over time. People who are accustomed to a sedentary lifestyle may find it particularly challenging to start and continue with an exercise program. Talk with a healthcare provider about any barriers that stand in the way of exercise; he or she may be able to suggest solutions.",
"    </p>",
"    <p>",
"     People with diabetic eye complications (proliferative retinopathy) may be advised to avoid high-impact activities and strenuous weight-lifting, which can increase blood pressure and cause bleeding in the eye. People with neurologic complications (peripheral neuropathy) are usually advised to avoid traumatic weight-bearing exercises such as running, which can lead to foot ulcers and stress fractures although this depends on the severity of the nerve damage. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=see_link\">",
"      \"Patient information: Diabetic neuropathy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Intensity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exercise does not have to be intense to be beneficial. Persons who want to increase the intensity of exercise should do so gradually, and should stop if he or she experiences worrisome symptoms, such as chest discomfort or nausea.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Duration",
"     </span>",
"     &nbsp;&mdash;&nbsp;A reasonable exercise session consists of 10 minutes of stretching and warm-up, followed by 20 minutes of gentle aerobic exercise. Eventually, you may wish to exercise for more than 30 minutes at a time. You should increase the duration of exercise gradually.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Timing",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who take insulin should try to exercise at the same time of the day. This practice can help to maintain predictable blood sugar levels.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Frequency",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most of the benefits of exercise for people with diabetes require a regular, long-term exercise program. Patients should commit to exercising 30 minutes a day most days of the week.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      QUITTING SMOKING",
"     </span>",
"    </p>",
"    <p>",
"     Over 25 percent of people newly diagnosed with diabetes are smokers. Quitting smoking is one of the most important things a patient can do to improve their health. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      \"Patient information: Quitting smoking (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Smokers with diabetes have an increased risk of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Death, especially from heart attacks and strokes",
"      </li>",
"      <li>",
"       High LDL (\"bad\") cholesterol levels",
"      </li>",
"      <li>",
"       Worsened blood sugar controlled, compared to non-smokers",
"      </li>",
"      <li>",
"       Nerve damage from diabetes",
"      </li>",
"      <li>",
"       Kidney disease leading to dialysis",
"      </li>",
"      <li>",
"       Foot ulcer and amputation of toes, feet or legs caused by peripheral vascular disease (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"        \"Patient information: Peripheral artery disease and claudication (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Diabetics who quit smoking can decrease their risks. Most people who smoke find it difficult to quit; assistance is available from a number of sources. Healthcare providers have access to self-help materials, and can help select a quit date, provide contact information for local support groups, and prescribe nicotine replacement treatment, if needed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      DIET AND TYPE 2 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Changing the type and amount of food eaten can help people with diabetes to lose weight, improve blood sugar control, and lower blood cholesterol levels and blood pressure. A separate topic discusses these issues in detail. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=see_link\">",
"      \"Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      MEDICATIONS AND BLOOD SUGAR MONITORING IN TYPE 2 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     The day-to-day management of blood sugar levels can be complicated. The daily regimen may include oral medications",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     insulin, blood sugar monitoring, and carefully planned meals and snacks.",
"    </p>",
"    <p>",
"     However, successful management of diabetes does not have to take the enjoyment out of life. It can be difficult to establish a routine that incorporates all aspects of diabetes care, although many people find that the routine becomes second nature over time. Written schedules may help patients to remember the details of a routine until they are committed to memory. It is also important to carefully manage situations that can complicate blood sugar control, such as sick days and vacations.",
"    </p>",
"    <p>",
"     People with diabetes may need to take several medications throughout the day. Medications to lower high blood pressure, lower cholesterol levels, and low-dose aspirin may be used to manage and prevent complications. Each prescription should be taken exactly as directed on a daily basis. If the medication schedule is complex, a pill organizer or written outline may be helpful in remembering to take specific medications at specific times.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      ROUTINE MEDICAL CARE IN TYPE 2 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Making changes in diet and exercise are an important step in diabetes management. However, routine medical care is also important to long-term health for people with diabetes, particularly when it comes to preventing, detecting, and slowing the progression of complications. A healthcare provider can recommend a regular schedule for visits, screening, and monitoring tests based upon the duration of the disease, any complications, and other medical problems.",
"    </p>",
"    <p>",
"     Your healthcare team will periodically reevaluate your management plan, and can work to detect health problems that do not cause symptoms in the early stages.",
"    </p>",
"    <p>",
"     Regular screening for non-diabetes related health problems is also recommended.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       For women, this may include a cervical cancer screening, mammogram and clinical breast exam, and bone density testing. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"        \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"        \"Patient information: Breast cancer screening (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"        \"Patient information: Bone density testing (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       For men, prostate cancer screening may be recommended after age 50. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=see_link\">",
"        \"Patient information: Prostate cancer screening (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       For both men and women, colon cancer screening is recommended after age 50. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"        \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H151\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14371539\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=see_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/25/15763?source=see_link\">",
"      Patient information: Preventing type 2 diabetes (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14371583\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"      Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=see_link\">",
"      Patient information: Diabetic neuropathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=see_link\">",
"      Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=see_link\">",
"      Patient information: Prostate cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5189?source=see_link\">",
"      Smoking and cardiovascular risk in diabetes mellitus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/diabetes.cfm\">",
"      www.hormone.org/public/diabetes.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?5/60/6083/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?5/60/6083?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6083/abstract/1\">",
"      Close EJ, Wiles PG, Lockton JA, et al. The degree of day-to-day variation in food intake in diabetic patients. Diabet Med 1993; 10:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6083/abstract/2\">",
"      Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6083/abstract/3\">",
"      Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 1994; 17:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6083/abstract/4\">",
"      Torjesen PA, Birkeland KI, Anderssen SA, et al. Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. Diabetes Care 1997; 20:26.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f5_60_6083=[""].join("\n");
var outline_f5_60_6083=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           TYPE 2 DIABETES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ALCOHOL AND TYPE 2 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           EXERCISE AND TYPE 2 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           QUITTING SMOKING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           DIET AND TYPE 2 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           MEDICATIONS AND BLOOD SUGAR MONITORING IN TYPE 2 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           ROUTINE MEDICAL CARE IN TYPE 2 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f5_60_6084="Vitamin B1 (thiamine): Pediatric drug information";
var content_f5_60_6084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin B1 (thiamine): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/9/147?source=see_link\">",
"    see \"Vitamin B1 (thiamine): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/53/18260?source=see_link\">",
"    see \"Vitamin B1 (thiamine): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Betaxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Water Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adequate intake: Oral: 0.2 mg (0.03 mg/kg)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/9/147?source=see_link\">",
"      see \"Vitamin B1 (thiamine): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adequate intake: Oral: Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 to &lt;6 months: 0.2 mg (0.03 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 months: 0.3 mg (0.03 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recommended daily allowance (RDA): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 0.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 0.9 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Male: 1.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Female: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;19 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Male: 1.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Female: 1.1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dietary supplement (depends on caloric or carbohydrate content of the diet):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants: 0.3-0.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 0.5-1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 1-2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The above doses can be found in multivitamin preparations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Thiamine deficiency (beriberi):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 10-25 mg/dose I.M. or I.V. daily (if critically ill), or 10-50 mg/dose orally every day for 2 weeks, then 5-10 mg/dose orally daily for 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 5-30 mg/dose I.M. or I.V. 3 times/day (if critically ill); then orally 5-30 mg/day in single or divided doses 3 times/day for 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wernicke's encephalopathy: Adults: Initial: 100 mg I.V., then 50-100 mg/day I.M. or I.V. until consuming a regular, balanced diet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolic disorders: Oral: Adults: 10-20 mg/day (dosages up to 4 g/day in divided doses have been used)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F226731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 100 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 50 mg, 100 mg, 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F226717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with or without food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Administer by slow I.V. injection or I.M.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F226797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, fat emulsion 10%, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Famotidine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Doxapram, potassium chloride.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amobarbital, furosemide.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unstable with alkaline or neutral solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of thiamine deficiency including beriberi, Wernicke's encephalopathy syndrome, and peripheral neuritis associated with pellagra; alcoholic patients with altered sensorium; various genetic metabolic disorders",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F226798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Thiamine may be confused with Tenormin&reg;, Thalomid&reg;, Thorazine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal [Brazil] may be confused with Doxil brand name for doxorubicin [U.S.]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal: Brand name for pyridoxine/thiamine [Brazil], but also the brand name for doxepin [Finland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F226796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions reported with injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Cyanosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Angioneurotic edema, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Hemorrharge into GI tract, nausea, tightness of the throat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Induration and/or tenderness at the injection site (following I.M. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylactic/hypersensitivity reactions (following I.V. administration), diaphoresis, warmth",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to thiamine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use parenteral route cautiously",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Large doses should be given in divided doses for better oral absorption",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1062576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High carbohydrate diets may increase thiamine requirement",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F226728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3423333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Water soluble vitamins cross the placenta. Thiamine requirements may be increased during pregnancy (IOM, 1998). Severe nausea and vomiting (hyperemesis gravidarum) may lead to thiamine deficiency manifested as Wernicke&rsquo;s encephalopathy (Chiossi, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1062569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Normal values: 1.6-4 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An essential coenzyme in carbohydrate metabolism; combines with adenosine triphosphate to form thiamine pyrophosphate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renally as unchanged drug only after body storage sites become saturated",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/53/18260?source=see_link\">",
"      see \"Vitamin B1 (thiamine): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May color urine bright yellow",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary sources include legumes, pork, beef, whole grains, yeast, fresh vegetables; a deficiency state can occur in as little as 3 weeks following total dietary absence",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10951005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 100 mg/mL oral suspension may be made with commercially available thiamine powder. Add 10 g of powder to a mortar. Add small portions of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; and mix to a uniform paste; mix while adding the vehicle in equal proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 100 mL. Label \"shake well\". Stable 91 days under refrigeration or at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Ensom MH and Decarie D, \"Stability of Thiamine in Extemporaneously Compounded Suspensions,\"",
"     <i>",
"      Can J Hosp Pharm",
"     </i>",
"     , 2005, 58(1):26-30.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12833 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.244-3BAB8F1ACB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6084=[""].join("\n");
var outline_f5_60_6084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226752\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062567\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445204\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062560\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226731\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226717\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062571\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226797\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062564\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062570\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226798\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226796\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062574\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062559\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062558\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300131\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223291\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062576\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226728\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3423333\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062569\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062557\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062573\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062566\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062575\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10951005\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12833\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12833|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/9/147?source=related_link\">",
"      Vitamin B1 (thiamine): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/53/18260?source=related_link\">",
"      Vitamin B1 (thiamine): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_60_6085="Guaifenesin and pseudoephedrine: Patient drug information";
var content_f5_60_6085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Guaifenesin and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/40/22148?source=see_link\">",
"     see \"Guaifenesin and pseudoephedrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ambifed-G [OTC];",
"     </li>",
"     <li>",
"      Congestac&reg; [OTC];",
"     </li>",
"     <li>",
"      ExeFen-IR;",
"     </li>",
"     <li>",
"      Maxifed [OTC];",
"     </li>",
"     <li>",
"      Maxifed-G [OTC] [DSC];",
"     </li>",
"     <li>",
"      Mucinex&reg; D Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; D [OTC];",
"     </li>",
"     <li>",
"      Refenesen Plus [OTC];",
"     </li>",
"     <li>",
"      SudaTex-G [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Contac&reg; Cold-Chest Congestion, Non Drowsy, Regular Strength;",
"     </li>",
"     <li>",
"      Entex&reg; LA;",
"     </li>",
"     <li>",
"      Novahistex&reg; Expectorant with Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin mucous so it can be taken from the body by coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to guaifenesin, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad heart disease or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12524 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6085=[""].join("\n");
var outline_f5_60_6085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177863\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177864\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021332\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021334\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021333\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021338\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021339\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021341\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021336\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021337\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021342\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021343\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/40/22148?source=related_link\">",
"      Guaifenesin and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_60_6086="Cervical cytology: Evaluation of low grade squamous intraepithelial lesions";
var content_f5_60_6086=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6086/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6086/contributors\">",
"     Anne Kathryn Goodman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6086/contributors\">",
"     Christine H Holschneider, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6086/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6086/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6086/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6086/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/60/6086/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the evaluation of women with low grade squamous intraepithelial lesions (LSIL) detected during cytological screening for cervical cancer. Evaluation of women with other cervical cytological findings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28517?source=see_link\">",
"     \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"      \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colposcopy/biopsy",
"    is the preferred method of evaluating most women with LSIL, given the relatively high risk (12 to 16 percent) of underlying cervical intraepithelial neoplasia (CIN) 2,3 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Exceptions are discussed below (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Special populations'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Reflex HPV testing is not useful for reducing the frequency of colposcopy referrals because LSIL can be considered a cytological manifestation of infection with a high oncogenic risk HPV virus (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"     table 1",
"    </a>",
"    ): 77 percent of women with LSIL test positive for these viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/4\">",
"     4",
"    </a>",
"    ]. In a study in which two independent methods for HPV testing and several cytologic definitions of LSIL were used, only 3 to 11 percent of patients with LSIL were HPV negative, and these cases likely represented false positive cytology or false negative HPV testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, repeat cytologic evaluation is not a cost-effective means of reducing colposcopy referrals. If ASC-US or greater is used as the threshold for referral during follow-up, 80 percent of women with LSIL on their initial smear will eventually require colposcopy due to repeated cytologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of CIN 2,3 in women with LSIL is similar to that in women with ASC-US plus a positive high risk HPV test [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/3\">",
"     3",
"    </a>",
"    ]; for this reason, evaluation of these two groups of women is the same (ie, colposcopy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer screening of adolescents (defined as ages 13 to 20 according to the American Society for Colposcopy and Cervical Pathology [ASCCP] guidelines) is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended by the American College of Obstetricians and Gynecologists (ACOG); the only exceptions to this are adolescents infected with human immunodeficiency virus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This recommendation is consistent with guidelines for other professional societies. In the general adolescent patient population, the prevalence of transient HPV infection (and transient cytologic abnormality) is very high while the prevalence of invasive cancer is near zero [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H22#H22\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Initial screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a pap test is inadvertently done in an adolescent and shows LSIL, then colposcopy is not required and cytology should be repeated in 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The rationale for this approach is that LSIL (like ASC-US) generally represents a transient HPV infection in adolescents and both the infection and LSIL usually resolve over time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Furthermore, the rate of invasive cervical cancer in this age group is near zero.",
"   </p>",
"   <p>",
"    After 12 months, colposcopy is reasonable if cytology shows HSIL or greater; otherwise, repeat cytological evaluation in another 12 months is appropriate. After 24 months, ASC-US or a more severe abnormality warrants referral for colposcopy, given that transient HPV infections and the mild cytological abnormalities associated with them typically have resolved by this time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5512?source=see_link\">",
"     \"Consent in adolescent health care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated in a study involving 187 adolescents aged 13 to 22 years with LSIL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/13\">",
"     13",
"    </a>",
"    ]. Sixty-one percent of the lesions had regressed within one year and 91 percent regressed within three years; 3 percent progressed to HSIL. The high rate of regression may be related to the high rate of resolution of HPV infection in young women and the fact that LSIL reflects the cellular changes associated with HPV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/14\">",
"     14",
"    </a>",
"    ]. However, at least one study suggested that rates of regression and progression are similar to those in adult women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal women have three options for further evaluation of LSIL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These options are similar to those of women with ASC-US:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immediate colposcopy",
"     </li>",
"     <li>",
"      Reflex HPV testing",
"     </li>",
"     <li>",
"      Repeat cytologic evaluation at 6 and 12 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to adolescents and premenopausal women with LSIL, performing a test for HPV in postmenopausal women with LSIL is useful for triage to colposcopy because of the low prevalence of HPV infection in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. If HPV testing is negative for high oncogenic risk HPV types (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"     table 1",
"    </a>",
"    ), the risk of an underlying high grade lesion is very low so further follow-up with repeat cytologic evaluation at 12 months is acceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. We generally manage our patients with either immediate colposcopy or reflex HPV testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colposcopic evaluation is recommended for evaluation of LSIL in non adolescent pregnant women; however, colposcopy may be deferred until six weeks postpartum (to allow the cervix to return to its nonpregnant state). Endocervical curettage is NOT performed in pregnancy, but biopsies of lesions suspicious for CIN 2,3 or cancer are obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/18\">",
"     18",
"    </a>",
"    ]. Pregnant woman with colposcopic impression of only CIN 1 may forgo biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study on the natural history of SIL in pregnancy identified 129 women with LSIL on a first trimester antepartum cervical cytology smear; all were followed with colposcopy and biopsy, as indicated, during pregnancy and at six to eight weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/20\">",
"     20",
"    </a>",
"    ]. Postpartum, cervical cytology was normal in 62 percent",
"    <span class=\"nowrap\">",
"     (80/129),",
"    </span>",
"    LSIL persisted in 32 percent",
"    <span class=\"nowrap\">",
"     (41/129)",
"    </span>",
"    and progressed to HSIL in 6 percent",
"    <span class=\"nowrap\">",
"     (8/129).",
"    </span>",
"    Persistence and progression occurred primarily in women with a history of SIL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COLPOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The colposcopy and biopsy procedures are described in detail separately. Endocervical curettage (ECC) is NOT performed in pregnant women. In nonpregnant non adolescent women, ECC is recommended if no lesion is identified or the examination is unsatisfactory, but may be performed even in the setting of a satisfactory colposcopy with identification of a lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"     \"Colposcopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POSTCOLPOSCOPY MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Colposcopy/biopsy shows CIN 2 or 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;CIN 2,3 or invasive disease is treated as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Colposcopy/biopsy shows CIN 1 or less",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 10 to 15 percent of premenopausal women with CIN 1 or less will develop CIN 2 or 3 within two years; therefore, enhanced follow-up is desirable. It is acceptable to either repeat cytological examination at 6 and 12 months or perform HPV testing at 12 months, with colposcopy for ASC or higher or a positive HPV test [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. HPV positivity at 12 months indicates persistent infection, which places the patient in a group at high risk for developing high grade disease. Women with two consecutive negative cytology results or a negative HPV test can resume routine screening. There is no role for additional diagnostic excisional procedures in these women, given the low risk of invasive cancer.",
"   </p>",
"   <p>",
"    Support for this approach was derived from a study comparing postcolposcopy management strategies for women referred for LSIL with CIN 1 or less at initial colposcopy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6086/abstract/21\">",
"     21",
"    </a>",
"    ]. HPV testing at 12 months and repeat semiannual cytology with referral to colposcopy for ASC-US or more or a positive HPV test had similar sensitivity for detection of CIN 2,3 (92 and 88 percent, respectively), but HPV testing allowed more patients to avoid repeat colposcopy (45 versus 36 percent). Combining cytology and HPV testing did not increase sensitivity and lowered specificity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women &mdash; Follow-up of pregnant women with LSIL and a biopsy showing CIN 1 or less is unnecessary during pregnancy; in this setting, the probability of developing of a serious lesion requiring treatment during pregnancy is remote. Follow-up can be deferred until the woman is at least six weeks postpartum.",
"     </li>",
"     <li>",
"      Postmenopausal women &mdash; The risk of an underlying high grade lesion is very low in postmenopausal women with CIN 1 or less. Therefore, further evaluation with repeat cytologic evaluation at 12 months is acceptable. Excision or ablation is an acceptable alternative to monitoring in the patient who is at high risk of loss to follow-up or who has other risk factors for disease progression, such as immunosuppression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"       \"Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=see_link\">",
"       \"Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"       \"Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In premenopausal women with low grade squamous intraepithelial lesions (LSIL) on cervical cytology, immediate colposcopy is the preferred method of evaluation, given the relatively high risk of underlying CIN 2,3 or more. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Premenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In postmenopausal women with LSIL, options for further evaluation include: immediate colposcopy, repeat cytologic evaluation at 6 and 12 months, and HPV testing. In contrast to adolescents and premenopausal women, HPV testing can be useful for allowing many women to avoid colposcopy since the prevalence of HPV infection in this population is low. If HPV testing is negative for high oncogenic risk HPV types (",
"      <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"       table 1",
"      </a>",
"      ), the patient should be followed with a repeat cytologic evaluation in 12 months. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Postmenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pregnant women with LSIL, we perform colposcopy, but the procedure can be deferred until six weeks postpartum, when the cervix has returned to its nonpregnant status. Endocervical curettage is NOT performed in pregnancy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 10 to 15 percent of premenopausal women evaluated for LSIL who have CIN 1 or less on biopsy will develop CIN 2,3 within two years. Given this risk, we suggest monitoring these women with either repeat cytological examination at 6 and 12 months or HPV testing at 12 months. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Postcolposcopy management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/1\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197:346.",
"     </a>",
"    </li>",
"    <li>",
"     www.ASCCP.org (Accessed on April 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/3\">",
"      Cox JT, Schiffman M, Solomon D, ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/4\">",
"      Arbyn M, Sasieni P, Meijer CJ, et al. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24 Suppl 3:S3/78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/5\">",
"      Zuna RE, Wang SS, Rosenthal DL, et al. Determinants of human papillomavirus-negative, low-grade squamous intraepithelial lesions in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS). Cancer 2005; 105:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/6\">",
"      ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003; 188:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/7\">",
"      Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol 2012; 120:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/8\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 463: Cervical cancer in adolescents: screening, evaluation, and management. Obstet Gynecol 2010; 116:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/9\">",
"      Boardman LA, Stanko C, Weitzen S, Sung CJ. Atypical squamous cells of undetermined significance: human papillomavirus testing in adolescents. Obstet Gynecol 2005; 105:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/10\">",
"      Sherman ME, Solomon D, Schiffman M, ASCUS LSIL Triage Study Group. Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. Am J Clin Pathol 2001; 116:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/11\">",
"      Wright JD, Pinto AB, Powell MA, et al. Atypical squamous cells of undetermined significance in girls and women. Obstet Gynecol 2004; 103:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/12\">",
"      Wright JD, Davila RM, Pinto KR, et al. Cervical dysplasia in adolescents. Obstet Gynecol 2005; 106:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/13\">",
"      Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/14\">",
"      Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/15\">",
"      Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001; 183:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/16\">",
"      Sherman ME, Schiffman M, Cox JT, Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2002; 94:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/17\">",
"      Evans MF, Adamson CS, Papillo JL, et al. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 2006; 106:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/18\">",
"      Economos K, Perez Veridiano N, Delke I, et al. Abnormal cervical cytology in pregnancy: a 17-year experience. Obstet Gynecol 1993; 81:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/19\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin number 66, September 2005. Management of abnormal cervical cytology and histology. Obstet Gynecol 2005; 106:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/20\">",
"      Kaplan KJ, Dainty LA, Dolinsky B, et al. Prognosis and recurrence risk for patients with cervical squamous intraepithelial lesions diagnosed during pregnancy. Cancer 2004; 102:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6086/abstract/21\">",
"      Guido R, Schiffman M, Solomon D, et al. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003; 188:1401.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3206 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6086=[""].join("\n");
var outline_f5_60_6086=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COLPOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POSTCOLPOSCOPY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Colposcopy/biopsy shows CIN 2 or 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Colposcopy/biopsy shows CIN 1 or less",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3206\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3206|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/27/443\" title=\"table 1\">",
"      Risk of cervical CA with HPV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=related_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28517?source=related_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5512?source=related_link\">",
"      Consent in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=related_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=related_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=related_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_60_6087="Rubella in pregnancy";
var content_f5_60_6087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rubella in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6087/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6087/contributors\">",
"     Laura E Riley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6087/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6087/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6087/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6087/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/60/6087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubella, also known as German measles, was a disease of childhood that has markedly declined in incidence in the United States since the introduction of routine childhood rubella vaccination. This virus causes a self-limited infection in most hosts, but can have potentially devastating effects on the developing fetus. Screening for antibodies to rubella is routinely performed by obstetricians.",
"   </p>",
"   <p>",
"    Rubella virus is a member of the togavirus family, genus Rubivirus, and humans are the only reservoir for rubella infection. The virus is transmitted by direct droplet contact from nasopharyngeal secretions, replicates in the lymph tissue of the upper respiratory tract, and spreads hematogenously. Congenital infection occurs when maternal viremia allows hematogenous spread of the virus across the placenta.",
"   </p>",
"   <p>",
"    Rubella in pregnancy will be reviewed here. The virology, pathogenesis, clinical manifestations, diagnosis, treatment, and prevention through vaccination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=see_link\">",
"     \"Rubella\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubella and the congenital rubella syndrome (CRS) have largely been eliminated in the United States. The incidence of rubella has declined from 0.45 per 100,000 in 1990 to 0.1 per 100,000 in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/1\">",
"     1",
"    </a>",
"    ]. However, rubella outbreaks continue to occur in other parts of the world, and CRS remains a concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the introduction of the rubella vaccine in 1969, epidemics of rubella occurred in six to nine year cycles, usually in the late winter and early spring. In 1964, a major worldwide pandemic spread to the United States resulting in approximately 12.5 million cases of rubella, as many as 11,000 fetal deaths, and approximately 20,000 cases of congenital rubella syndrome (CRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the introduction of a comprehensive vaccine program, the epidemiologic evidence in 2004 suggests that rubella is no longer endemic in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/3\">",
"     3",
"    </a>",
"    ]. During 1998 to 2000, the median number of reported rubella cases was 272, whereas, during 2001 to 2004, the median number reported was 13. Since 2001, only five infants with CRS have been reported; three were born in 2001, one in 2003, and one in 2004.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other regions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of rubella susceptible women of childbearing age varies greatly among nations, especially the developing countries. As examples, an estimated 15 percent of women between the ages of 20 and 29 lack antibodies to rubella in Turkey [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/4\">",
"     4",
"    </a>",
"    ], and 23 percent of women of childbearing age had negative titers in Nigeria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/5\">",
"     5",
"    </a>",
"    ]. In the Russian Federation, 16.5 percent of pregnant women were susceptible to rubella, and CRS occurred in approximately 3.5 cases per 1000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/6\">",
"     6",
"    </a>",
"    ]. Fifteen percent of 342 infants with suspected congenital infections had detectable IgM against rubella in one study in India [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rubella cases declined by 98 percent in the Americas between 1998 and 2006 (from 135,947 to 2998). In 2007, there were large outbreaks in Argentina, Brazil, and Chile, primarily in men, which prompted new vaccination campaign strategies to include men and women in an effort to eliminate rubella and CRS by 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/8\">",
"     8",
"    </a>",
"    ]. Immigrants are also the source of CRS in other developed countries, such as the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/9\">",
"     9",
"    </a>",
"    ] and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/10\">",
"     10",
"    </a>",
"    ]. Among women living in or immigrating from developing countries, one should consider the possibility that a positive rubella screening test result at the first prenatal visit may be a sign of recent active infection, rather than evidence of immunity from old infection or vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in countries where rubella vaccination programs are available, the extent of vaccination is not always optimal. One group reported that although more than one-third of counties had a national vaccination policy, 9 percent reported a selective strategy (ie, protection to women or schoolgirls), and 31 percent reported only childhood immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/12\">",
"     12",
"    </a>",
"    ]. These selective strategies allow for some segments of the population to remain unvaccinated. Unvaccinated susceptibles can be a source of many preventable cases of CRS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/13\">",
"     13",
"    </a>",
"    ]. This theoretical concern was demonstrated to be of significance in Greece; vaccination coverage in the country was &lt;50 percent and the number of susceptible pregnant women increased throughout the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/14\">",
"     14",
"    </a>",
"    ]. A major epidemic of rubella occurred in 1993; the mean age of affected patients was 17 years, and 64 percent were over the age of 15. The incidence of CRS in 1993 rose dramatically, from one to four cases per year before that time to 25 cases (24.6 cases per 100,000 live births). Similarly, in the United States, some areas note declining vaccination rates, which leads to more sporadic cases of rubella and provides a reservoir for transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired rubella is generally a mild, self-limited disease associated with a characteristic exanthem (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=see_link\">",
"     \"Rubella\"",
"    </a>",
"    ). Symptoms appear approximately 14 to 21 days after inoculation with the virus. Though asymptomatic in 25 to 50 percent of cases, affected individuals may experience mild, prodromal symptoms consisting of low-grade fever, conjunctivitis, coryza, sore throat, cough, and occasionally headache and malaise. These symptoms usually last one to five days before the onset of the rash. Rubella may also be associated with generalized, tender lymphadenopathy, particularly involving suboccipital, postauricular, and cervical nodes, which often becomes pronounced during the rash. Just prior to the onset of the rash, approximately 20 percent of those infected will develop discrete rose spots on the soft palate (Forchheimer spots) that may later expand and coalesce.",
"   </p>",
"   <p>",
"    The typical rash of rubella is an erythematous maculopapular eruption, which may be mildly pruritic and evolves into pinpoint papules similar to scarlet fever. The rash characteristically begins on the face and spreads to the trunk and extremities within hours. It lasts approximately one to three days and resolves first from the face and then from the body.",
"   </p>",
"   <p>",
"    Polyarthritis and polyarthralgia are potential sequelae. Rheumatologic symptoms may develop about one week after the rash and are more commonly seen in female adolescents and adults, occurring in as many as 60 to 70 percent of adult women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/16\">",
"     16",
"    </a>",
"    ]. Classically, the hands, knees, wrists, and ankles are affected in a symmetric pattern with pain and morning stiffness for one to four weeks. Chronic arthritis rarely develops. Tenosynovitis and carpal tunnel syndrome may also be associated with rubella. Other rare complications include: thrombocytopenia associated with purpura or hemorrhage, postinfectious encephalitis, myocarditis, pericarditis, hepatitis, hemolytic anemia, and hemolytic uremic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Congenital rubella syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubella infection can have catastrophic effects on the developing fetus, resulting in spontaneous abortion, fetal infection, stillbirth, or intrauterine growth restriction. This area is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=see_link\">",
"     \"Congenital rubella syndrome: Management, outcome, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal-fetal transmission occurs via hematogenous spread and varies with gestational age. There is considerable pathologic evidence that suggests that the rubella virus spreads through the vascular system of the developing fetus after infecting the placenta. The resulting defects stem from cytopathic damage to blood vessels and ischemia in affected organs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/19\">",
"     19",
"    </a>",
"    ]. In the first trimester, fetal infection rates as high as 81 percent have been observed, dropping to 25 percent in the late second trimester and increasing again in the third trimester from 35 percent at 27 to 30 weeks to nearly 100 percent for fetuses exposed beyond 36 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the risk of congenital defects after maternal infection is essentially limited to maternal infection in the first 16 weeks of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/21\">",
"     21",
"    </a>",
"    ]. Little, if any, risk of CRS is associated with infection after 20 weeks&rsquo; gestation, and intrauterine growth retardation may be the only sequelae of third trimester infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/20,22-24\">",
"     20,22-24",
"    </a>",
"    ]. Similarly, there is no evidence that rubella infection immediately prior to pregnancy increases the risk of congenital infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, maternal immunity, either vaccine or naturally derived, is protective against intrauterine rubella infection. However, there have been CRS cases resulting from maternal reinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. None of these cases occurred in women infected after 12 weeks&rsquo; gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serology is widely available and may be used to screen for rubella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/30\">",
"     30",
"    </a>",
"    ]. Enzyme linked immunoassays (ELISA) are sensitive, easy to perform, and measure rubella-specific IgG and IgM. Immunofluorescent antibody assays are also sensitive and rapid; commercial IgG and IgM assays are available. Other serologic tests include passive hemagglutination antibody (PHA), latex agglutination, complement fixation, and hemagglutination inhibition (HI). Most laboratories use ELISA due to its convenience, sensitivity, and accuracy. The clinical diagnosis of rubella should only be made in typical cases occurring during an epidemic.",
"   </p>",
"   <p>",
"    Acute rubella syndrome is best diagnosed by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A fourfold rise in IgG titer between acute and convalescent serum specimens",
"     </li>",
"     <li>",
"      The presence of rubella specific IgM",
"     </li>",
"     <li>",
"      A positive rubella culture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum should be obtained within 7 to 10 days after the onset of the rash and repeated two to three weeks later. Rubella virus may be isolated from nasal, blood, throat, urine, or cerebrospinal fluid (CSF) specimens. The virus is generally isolated from the pharynx one week before to two weeks after the rash. Viral isolates can be typed to facilitate surveillance during outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) is another option for providing presumptive diagnosis of rubella infection. This method has been used extensively in the United Kingdom for detection of rubella virus in clinical specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/32\">",
"     32",
"    </a>",
"    ]. There are small series reporting the usefulness of PCR for prenatal diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A reverse transcription-nested PCR assay has been used in small studies where it detects rubella virus in chorionic villous samples (CVS) and amniotic fluid samples of affected pregnancies. The largest study to date reported 34 cases where PCR detection of rubella was better in CVS samples than amniotic fluid samples [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/35\">",
"     35",
"    </a>",
"    ]. A case report of maternal primary rubella in the second trimester also showed that amniotic fluid was negative by PCR at both 19 and 23 weeks, while fetal blood was positive at 23 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, rubella IgM on fetal blood was negative in eight infected cases, but PCR was positive in all eight. Although the numbers are small, it would appear that rubella specific PCR on CVS samples may be superior to standard serologic testing on fetal blood. In addition, CVS sampling ideally done at 10 to 12 weeks&rsquo; gestation would allow for earlier detection than other samples, such as fetal blood obtained at 18 to 20 weeks&rsquo; gestation.",
"   </p>",
"   <p>",
"    Ultrasound diagnosis of an affected fetus would be extremely difficult given the nature of the malformations seen with CRS, although, the workup of any fetus with intrauterine growth restriction should include evaluation for congenital viral infections including rubella.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for acute rubella infection may include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for symptomatic relief. Glucocorticoids, platelet transfusion, and other supportive measures are reserved for patients with complications such as thrombocytopenia or encephalopathy. The prognosis for pregnant women with rubella is generally excellent.",
"   </p>",
"   <p>",
"    However, because of the potentially devastating effects on the fetus, women should be counseled about maternal-fetal transmission and offered pregnancy termination, especially prior to 16 weeks&rsquo; gestation. After 20 weeks&rsquo; gestation, management should be individualized, and parents should be counseled about the potential for delayed consequences of rubella infection (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link&amp;anchor=H12#H12\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Late manifestations'",
"    </a>",
"    ). There is no definitively beneficial in utero treatment available for exposed or affected fetuses.",
"   </p>",
"   <p>",
"    The use of immune globulin for pregnant women with acute infection is controversial. There are no data to suggest that IgG has a beneficial effect on the fetal response to disease. Thus, the Centers for Disease Control and Prevention (CDC) recommends limiting the use of immune globulin to women with known rubella exposure who decline pregnancy termination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first live-attenuated rubella vaccines were introduced in 1969. RA",
"    <span class=\"nowrap\">",
"     27/3,",
"    </span>",
"    a live-attenuated vaccine, is the current vaccine used in the United States (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=see_link\">",
"     \"Rubella\"",
"    </a>",
"    ). A single dose of this vaccine given at one year of age or older results in measurable antibody in almost 95 percent of susceptible persons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccination is recommended for all children at 12 to 15 months and 4 to 6 years in conjunction with measles and mumps (MMR). All other persons should be vaccinated unless immunity is documented by serology.",
"   </p>",
"   <p>",
"    Postpartum vaccination programs have been shown to significantly reduce rubella susceptibility in pregnant seronegative women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/41\">",
"     41",
"    </a>",
"    ]. However, a study showed that in 2004, one-third of pregnant women were also susceptible to rubeola or mumps [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/42\">",
"     42",
"    </a>",
"    ]. The recommendation of the Centers for Disease Control and Prevention (CDC) and American Congress of Obstetricians and Gynecologists (ACOG) is that rubella susceptible women should receive MMR vaccine postpartum for protection against all of these viral pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/1,43\">",
"     1,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rubella vaccine virus may cross the placenta and infect the fetus. However, there have been no cases of CRS reported in women inadvertently vaccinated during early pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Therefore, pregnancy termination is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for these women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/43\">",
"     43",
"    </a>",
"    ]. Given the theoretical risks to the fetus, women had been advised to avoid pregnancy for three months following vaccination. The Advisory Committee on Immunization Practices (ACIP) has now shortened the recommended interval to 28 days after reviewing data from the United States, United Kingdom, Sweden, and Germany, which again confirmed no CRS cases in infants born to mothers who were vaccinated between two weeks before and six weeks after conception [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6087/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraindications to rubella vaccination include febrile illness, immunodeficiency disorder, history of anaphylaxis to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    , and pregnancy. Postpartum vaccination should be performed in all women known to be susceptible. Breastfeeding is not contraindicated. A small percentage of individuals will have side effects, such as arthritis, arthralgia, rash, adenopathy, or fever.",
"   </p>",
"   <p>",
"    The effectiveness of efforts to control and prevent rubella in the United States relies upon vaccination of susceptible individuals in all clinical settings with particular attention to persons born in countries lacking a comprehensive vaccination program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/10/14499?source=see_link\">",
"       \"Patient information: Rubella (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the introduction of a comprehensive vaccine program, rubella and congenital rubella syndrome (CRS) have largely been eliminated in the United States. However, in other parts of the world, particularly resource-limited settings, a considerable proportion of women of childbearing age remain susceptible to rubella, and thus CRS remains a concern. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquired rubella in the pregnant woman is generally a mild, self-limited disease characterized by an erythematous maculopapular eruption that is sometimes preceded by prodromal symptoms of low-grade fever, conjunctivitis, coryza, sore throat, and cough. Rheumatologic symptoms, including polyarthritis and arthralgias of the hands, wrists, knees, and ankles, commonly occur in women about a week following the rash. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=see_link&amp;anchor=H7#H7\">",
"       \"Rubella\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rubella infection of the fetus can be catastrophic, resulting in spontaneous abortion, stillbirth, congenital defects, and intrauterine growth retardation. Maternal-fetal transmission occurs via hematogenous spread and is highest in the first trimester and after 36 weeks&rsquo; gestation. However, the risk of congenital defects after maternal infection is essentially limited to maternal infection in the first 16 weeks of pregnancy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Congenital rubella syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link\">",
"       \"Congenital rubella syndrome: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunity to rubella in pregnant women should be documented as part of initial prenatal care. In susceptible pregnant women with suggestive clinical features, acute rubella syndrome can be diagnosed by one of the following (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H1272465#H1272465\">",
"       \"Initial prenatal assessment and patient education\", section on 'Rubella immunity'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A fourfold rise in IgG titer between acute (within 7 to 10 days of rash onset) and convalescent (two to three weeks later) serum specimens",
"     </li>",
"     <li>",
"      The presence of rubella-specific IgM",
"     </li>",
"     <li>",
"      A positive rubella culture (from nasal, blood, throat, urine, or cerebrospinal fluid samples)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women with documented acute rubella infection during pregnancy, fetal infection is diagnosed by testing chorionic villous samples (CVS) and amniotic fluid samples with a rubella-specific polymerase chain reaction (PCR) assay. Ultrasound findings are not specific for the prenatal diagnosis of CRS, but finding intrauterine growth retardation should prompt evaluation for congenital viral infections, including rubella. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women should be counseled about maternal-fetal transmission and offered pregnancy termination, especially when infection is diagnosed prior to 16 weeks&rsquo; gestation, due to the high risk for CRS. Otherwise, there is no definitively beneficial in utero treatment available for exposed or affected fetuses. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rubella vaccination can effectively protect against subsequent infection and is the best strategy to eliminate cases of CRS. The vaccine is live and may cross the placenta and theoretically infect the fetus; thus, it is contraindicated during pregnancy, and women are advised to avoid pregnancy for one month following vaccination. However, there have been no cases of CRS associated with the rubella vaccine, and thus pregnancy termination is not recommended for women who are inadvertently vaccinated during pregnancy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/1\">",
"      Reef SE, Frey TK, Theall K, et al. The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA 2002; 287:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/2\">",
"      Orenstein WA, Bart KJ, Hinman AR, et al. The opportunity and obligation to eliminate rubella from the United States. JAMA 1984; 251:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/3\">",
"      Reef SE, Redd SB, Abernathy E, et al. The epidemiological profile of rubella and congenital rubella syndrome in the United States, 1998-2004: the evidence for absence of endemic transmission. Clin Infect Dis 2006; 43 Suppl 3:S126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/4\">",
"      Aksit S, Egemen A, Ozacar T, et al. Rubella seroprevalence in an unvaccinated population in Izmir: recommendations for rubella vaccination in Turkey. Pediatr Infect Dis J 1999; 18:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/5\">",
"      Onyenekwe CC, Kehinde-Agbeyangi TA, Ofor US, Arinola OG. Prevalence of rubella-IgG antibody in women of childbearing age in Lagos, Nigeria. West Afr J Med 2000; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/6\">",
"      Semerikov VV, Lavrentyeva IN, Popov VF, et al. Rubella in the Russian Federation: epidemiological features and control measures to prevent the congenital rubella syndrome. Epidemiol Infect 2000; 125:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/7\">",
"      Ballal M, Shivananda PG. Prevalence of rubella virus in suspected cases of congenital infections. Indian J Pediatr 1997; 64:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward elimination of rubella and congenital rubella syndrome--the Americas, 2003-2008. MMWR Morb Mortal Wkly Rep 2008; 57:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/9\">",
"      Sheridan E, Aitken C, Jeffries D, et al. Congenital rubella syndrome: a risk in immigrant populations. Lancet 2002; 359:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/10\">",
"      McElroy R, Laskin M, Jiang D, et al. Rates of rubella immunity among immigrant and non-immigrant pregnant women. J Obstet Gynaecol Can 2009; 31:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/11\">",
"      Mehta NM, Thomas RM. Antenatal screening for rubella-infection or immunity? BMJ 2002; 325:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/12\">",
"      Robertson SE, Cutts FT, Samuel R, Diaz-Ortega JL. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella. Bull World Health Organ 1997; 75:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/13\">",
"      Cutts FT, Vynnycky E. Modelling the incidence of congenital rubella syndrome in developing countries. Int J Epidemiol 1999; 28:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/14\">",
"      Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 1999; 319:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/15\">",
"      Louie JK, Shaikh-Laskos R, Preas C, et al. Re-emergence of another vaccine-preventable disease?-Two cases of rubella in older adults. J Clin Virol 2009; 46:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/16\">",
"      Johnson RE, Hall AP. Rubella arthritis; report of cases studied by latex tests. N Engl J Med 1958; 258:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/17\">",
"      Ozsoylu S, Kanra G, Sava G. Thrombocytopenic purpura related to rubella infection. Pediatrics 1978; 62:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/18\">",
"      Bayer WL, Sherman FE, Michaels RH, et al. Purpura in congenital and acquired rubella. N Engl J Med 1965; 273:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/19\">",
"      Webster WS. Teratogen update: congenital rubella. Teratology 1998; 58:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/20\">",
"      Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982; 2:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/21\">",
"      Morgan-Capner P, Miller E, Vurdien JE, Ramsay ME. Outcome of pregnancy after maternal reinfection with rubella. CDR (Lond Engl Rev) 1991; 1:R57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/22\">",
"      Grillner L, Forsgren M, Barr B, et al. Outcome of rubella during pregnancy with special reference to the 17th-24th weeks of gestation. Scand J Infect Dis 1983; 15:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/23\">",
"      Peckham C. Congenital rubella in the United Kingdom before 1970: the prevaccine era. Rev Infect Dis 1985; 7 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/24\">",
"      Peckham CS. Clinical and laboratory study of children exposed in utero to maternal rubella. Arch Dis Child 1972; 47:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/25\">",
"      Enders G, Nickerl-Pacher U, Miller E, Cradock-Watson JE. Outcome of confirmed periconceptional maternal rubella. Lancet 1988; 1:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/26\">",
"      Bullens D, Smets K, Vanhaesebrouck P. Congenital rubella syndrome after maternal reinfection. Clin Pediatr (Phila) 2000; 39:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/27\">",
"      Paludetto R, van den Heuvel J, Stagni A, et al. Rubella embryopathy after maternal reinfection. Biol Neonate 1994; 65:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/28\">",
"      Aboudy Y, Fogel A, Barnea B, et al. Subclinical rubella reinfection during pregnancy followed by transmission of virus to the fetus. J Infect 1997; 34:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/29\">",
"      Robinson J, Lemay M, Vaudry WL. Congenital rubella after anticipated maternal immunity: two cases and a review of the literature. Pediatr Infect Dis J 1994; 13:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/30\">",
"      Best JM, O'Shea S, Tipples G, et al. Interpretation of rubella serology in pregnancy--pitfalls and problems. BMJ 2002; 325:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/31\">",
"      Frey TK, Abernathy ES. Identification of strain-specific nucleotide sequences in the RA 27/3 rubella virus vaccine. J Infect Dis 1993; 168:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/32\">",
"      Bosma TJ, Corbett KM, O'Shea S, et al. PCR for detection of rubella virus RNA in clinical samples. J Clin Microbiol 1995; 33:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/33\">",
"      Bosma TJ, Corbett KM, Eckstein MB, et al. Use of PCR for prenatal and postnatal diagnosis of congenital rubella. J Clin Microbiol 1995; 33:2881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/34\">",
"      Ho-Terry L, Terry GM, Londesborough P. Diagnosis of foetal rubella virus infection by polymerase chain reaction. J Gen Virol 1990; 71 ( Pt 7):1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/35\">",
"      Tanemura M, Suzumori K, Yagami Y, Katow S. Diagnosis of fetal rubella infection with reverse transcription and nested polymerase chain reaction: a study of 34 cases diagnosed in fetuses. Am J Obstet Gynecol 1996; 174:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/36\">",
"      Tang JW, Aarons E, Hesketh LM, et al. Prenatal diagnosis of congenital rubella infection in the second trimester of pregnancy. Prenat Diagn 2003; 23:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/37\">",
"      Rubella prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep1990; 39(RR-15):1-18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/38\">",
"      Chang TW, DesRosiers S, Weinstein L. Clinical and serologic studies of an outbreak of rubella in a vaccinated population. N Engl J Med 1970; 283:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/39\">",
"      Davis WJ, Larson HE, Simsarian JP, et al. A study of rubella immunity and resistance to infection. JAMA 1971; 215:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/40\">",
"      Greaves WL, Orenstein WA, Hinman AR, Nersesian WS. Clinical efficacy of rubella vaccine. Pediatr Infect Dis 1983; 2:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/41\">",
"      Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/42\">",
"      Haas DM, Flowers CA, Congdon CL. Rubella, rubeola, and mumps in pregnant women: susceptibilities and strategies for testing and vaccinating. Obstet Gynecol 2005; 106:295.",
"     </a>",
"    </li>",
"    <li>",
"     Immunization during pregnancy. American College of Obstetricians and Gynecologists Technical Bulletin, #160 October 1991. In compendium of selected publications. p. 528-537.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/44\">",
"      Bart SW, Stetler HC, Preblud SR, et al. Fetal risk associated with rubella vaccine: an update. Rev Infect Dis 1985; 7 Suppl 1:S95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/45\">",
"      Centers for Disease Control (CDC). Rubella vaccination during pregnancy--United States, 1971-1988. MMWR Morb Mortal Wkly Rep 1989; 38:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/46\">",
"      Badilla X, Morice A, Avila-Aguero ML, et al. Fetal risk associated with rubella vaccination during pregnancy. Pediatr Infect Dis J 2007; 26:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6087/abstract/47\">",
"      Centers for Disease Control and Prevention (CDC). Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR Morb Mortal Wkly Rep 2001; 50:1117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8312 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6087=[""].join("\n");
var outline_f5_60_6087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other regions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Congenital rubella syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=related_link\">",
"      Congenital rubella syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=related_link\">",
"      Congenital rubella syndrome: Management, outcome, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/10/14499?source=related_link\">",
"      Patient information: Rubella (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=related_link\">",
"      Rubella",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_60_6088="Cilazapril and hydrochlorothiazide: Drug information";
var content_f5_60_6088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cilazapril and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/18/22821?source=see_link\">",
"    see \"Cilazapril and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5928248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cilazapril&reg;/Hctz;",
"     </li>",
"     <li>",
"      Inhibace&reg; Plus;",
"     </li>",
"     <li>",
"      Novo-Cilazapril/HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5928250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5928284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: See individual agents. Initiate therapy with combination product only after successful titration of individual agents to adequate blood pressure control. Dose is individualized; range: Cilazapril: 2.5-10 mg; Hydrochlorothiazide: 6.25-25 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5928285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Reduction of initial dose may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5928286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate renal impairment: Use with caution; reduced dosage may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is  not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13254319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cirrhotic patients: Use with caution; reduced dosage required.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 5/12.5: Cilazapril monohydrate 5 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Inhibace&reg; Plus 5/12.5: Cilazapril monohydrate 5 mg and hydrochlorothiazide 12.5 mg [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5928289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without food in the morning to avoid nocturia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F240576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-moderate hypertension; not indicated for initial treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5928258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Palpitation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (4%), fatigue (3%), somnolence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Polyuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Transient neutropenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute interstitial pneumonitis, acute pulmonary edema, acute renal failure, agranulocytosis, alkaline phosphatase increased, angina, angioedema, arthralgia, atrial fibrillation, bleeding time increased, bradycardia, BUN increased, cerebrovascular disorder, cholestatic hepatitis (with or without necrosis), depression, dermatitis, diaphoresis, diplopia, dyspepsia, dyspnea, erythema multiforme, extrasystoles, facial edema, GGT increased, gout, hemolytic anemia, hyperbilirubinemia, hyponatremia, hypotension (including postural), hypothermia, insomnia, leukorrhea, malaise, melena, MI, myalgia, neurosis, pancreatitis, paresthesia, paroniria, pemphigus, peripheral edema, peripheral ischemia, pruritus, pseudoporphyria, purpura, rash, Stevens-Johnson syndrome, stroke, tachycardia, thrombocytopenia, tinnitus, toxic epidermal necrolysis, transaminases increased, vertigo, vision abnormal, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5928253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cilazapril, hydrochlorothiazide, or any component of the formulation; hypersensitivity to other ACE inhibitors, thiazides or sulfonamide-derived drugs, history of angioedema related to previous treatment with an ACE inhibitor; anuria; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5928254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising the airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Use with extreme caution in patients with idiopathic or hereditary angioedema. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity. Hydrochlorothiazide can cause systemic lupus erythematosus (SLE) exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypovolemia: Use with caution in patients with hypovolemia; hypotension can occur. Carefully monitor blood pressure with the first dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; acute porphyritic attacks have occurred with hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal artery stenosis: Use cilazapril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Contraindicated in anuric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers: Concurrent use of angiotensin receptor blockers may increase the risk of clinically-significant adverse events (eg, renal dysfunction, hyperkalemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [Canadian Boxed Warning]:  Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lactose: Contains lactose; avoid use in patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5928276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5928251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [Canadian Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Use is contraindicated in pregnant women. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5928252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14265110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrochlorothiazide is excreted into breast milk; use of this combination is contraindicated in nursing women",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5928288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5928291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; BUN, serum creatinine, and electrolytes; liver function tests (at baseline and then periodically thereafter in patients with preexisting hepatic dysfunction); if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5928281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, &ldquo;Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):782-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/13678872/pubmed\" id=\"13678872\" target=\"_blank\">",
"        13678872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DR, Oliveria SA, Berlowitz DR, et al, &ldquo;Angioedema Incidence in US Veterens Initiating Angiotensin-Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2008, 51(6):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/18413488/pubmed\" id=\"18413488\" target=\"_blank\">",
"        18413488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenthal JH, &ldquo;Therapeutic Experience With Cilazapril,&rdquo;",
"      <i>",
"       J Cardiovasc Pharmacol",
"      </i>",
"      , 1994, 24(Suppl2):65-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Song JC and White CM, &ldquo;Clinical Pharmacokinetics and Selective Pharmacodynamics of New Angiotensin Converting Enzyme Inhibitors: An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2002, 41(3):207-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/11929321/pubmed\" id=\"11929321\" target=\"_blank\">",
"        11929321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/60/6088/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8795 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6088=[""].join("\n");
var outline_f5_60_6088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928248\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928250\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928284\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928285\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928286\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13254319\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950031\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217375\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928289\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F240576\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928258\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928253\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928254\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299044\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928276\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928251\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928252\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14265110\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928288\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928291\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928281\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8795\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8795|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/18/22821?source=related_link\">",
"      Cilazapril and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_60_6089="Chronic obstructive pulmonary disease: Risk factors and risk reduction";
var content_f5_60_6089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic obstructive pulmonary disease: Risk factors and risk reduction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6089/contributors\">",
"     Scott T Weiss, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6089/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6089/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/60/6089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic obstructive pulmonary disease (COPD) is the result of complex interplay between clinical and molecular (ie, genetic) risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/1\">",
"     1",
"    </a>",
"    ]. These interactions are the reason that two individuals may have identical clinical risk factors, but only one will develop COPD. Identifying risk factors for COPD and better understanding their interactions may lead to strategies that reduce the prevalence of COPD.",
"   </p>",
"   <p>",
"    Risk factors for COPD and strategies for risk reduction are discussed in this topic review. The clinical manifestations, diagnosis, staging, natural history, and treatment of COPD are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35351?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LUNG FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung function normally increases as the lungs grow during childhood and adolescence, peaks shortly after 20 years of age, and then begins to decline gradually (",
"    <a class=\"graphic graphic_figure graphicRef66030 \" href=\"UTD.htm?14/51/15166\">",
"     figure 1",
"    </a>",
"    ). Risk factors for chronic obstructive pulmonary disease (COPD) cause one or more abnormal patterns of lung function as shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef66030 \" href=\"UTD.htm?14/51/15166\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced lung growth",
"     </li>",
"     <li>",
"      Premature lung function decline",
"     </li>",
"     <li>",
"      Accelerated lung function decline",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accelerated lung function decline is most common. However, each of these abnormal patterns can reduce lung function to an extent that the individual is considered to have COPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definite risk factors for chronic obstructive pulmonary disease (COPD) include smoking and increased airway responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Environmental exposures other than smoking, atopy, and antioxidant deficiency may also be risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous epidemiologic studies indicate that cigarette smoking is overwhelmingly the most important risk factor for COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. As an example, a retrospective cohort study (n=8045) found that continuous smokers were more likely than never smokers to develop COPD over 25 years (36 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic influences may enhance an individual's susceptibility to the detrimental effects of cigarette smoke. This is supported by an observational study that found that bronchodilator responsiveness (a surrogate measure of risk for accelerated lung function decline) was increased among current or former smokers who had a first-degree relative with severe early-onset COPD, compared to current or former smokers who did not have such a relative [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoking both tobacco and marijuana synergistically increases the risk of COPD and respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Airway responsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased airway responsiveness to allergens or other external triggers is a risk factor for COPD, according to numerous observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/12-19\">",
"     12-19",
"    </a>",
"    ]. As an example, one retrospective cohort study (n = 9651) found that the incidence of COPD over 11 years was higher among individuals with increased airway responsiveness, compared to those without increased airway responsiveness (OR 4.5, 95% CI 3.3-6.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While it is certain that both airway responsiveness and smoking are independent risk factors for COPD, conflicting data make it unclear whether they interact. While several studies suggest that cigarette smoking increases the effect of airway responsiveness on the development of COPD, other studies do not [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/10,13-16\">",
"     10,13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Environmental exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies indicate that environmental exposure to particulate matter, dusts, gases, fumes, or organic antigens may also be a risk factor for COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/20-31\">",
"     20-31",
"    </a>",
"    ]. As an example, a population-based sample (n=8515) found that COPD was more common among those exposed to occupational dust than those who were unexposed (OR 1.5, 95% CI 1.17-2.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/20\">",
"     20",
"    </a>",
"    ]. COPD is also more common in women exposed to indoor biomass smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/26,32,33\">",
"     26,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Atopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopy may increase an individual's risk for COPD, according to an observational study of 1025 older men (mean age 61 years) without asthma who underwent baseline skin prick and pulmonary function testing and were then followed for a median of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/34\">",
"     34",
"    </a>",
"    ]. Atopy was considered present when there was a mean wheal size &ge;2 mm in response four antigens &mdash; house dust, mixed grasses, mixed trees, and ragweed. Atopy predicted an excess annual rate of decline of the FEV1 (9.5 mL per year) and the",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    (0.3 percent per year), compared to nonatopic patients. Animal studies provide further support that atopy and COPD are related [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antioxidant deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data suggesting that a deficiency of antioxidant vitamins (eg, vitamins C and E) may be a risk factor for COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. In theory, a deficiency of antioxidant vitamins leaves the host unable to defend itself against the destructive effects of oxidative radicals, which derive from both exogenous sources (eg, cigarette smoke) and endogenous sources (eg, lung phagocytes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bronchopulmonary dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchopulmonary dysplasia, also known as neonatal chronic lung disease (CLD), is a consequence of preterm birth that is defined by dependence on supplemental oxygen for more than 28 days post-partum. Radiographic emphysema and evidence of airflow limitation on pulmonary function testing have been noted in young adult survivors of moderate and severe bronchopulmonary dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25398?source=see_link\">",
"     \"Outcome of infants with bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary tuberculosis may contribute to airflow obstruction via endobronchial infection and subsequent bronchostenosis or via lung parenchymal destruction with loss of airway tethering. In a study of 8784 Chinese subjects aged 50 or older, radiographic evidence of prior pulmonary tuberculosis was associated with an increased risk for airflow obstruction, independent of cigarette smoking, biomass fuel exposure, and prior diagnosis of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\", section on 'Endobronchial tuberculosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MOLECULAR RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies indicate that molecular risk factors for chronic obstructive pulmonary disease (COPD) exist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/10,41-44\">",
"     10,41-44",
"    </a>",
"    ]. As an example, one observational study found that the risk of COPD was approximately three times higher among the first-degree relatives of patients who had severe premature COPD unrelated to alpha-1 antitrypsin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/43\">",
"     43",
"    </a>",
"    ]. The role of alpha-1 antitrypsin deficiency in COPD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Molecular risk factors for COPD have been assessed using several different methods, including studies of gene polymorphisms, antioxidant enzyme function, metalloproteinase dysregulation, and abnormalities that cause excess elastase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gene polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several gene polymorphisms (SNPs) have been identified that may increase the risk of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/45-50\">",
"     45-50",
"    </a>",
"    ]. Some examples are listed here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor necrosis factor alpha &mdash; Tumor necrosis factor-alpha (TNF-a) gene polymorphisms may favor the development of chronic bronchitis by influencing host immune responses and increasing inflammatory tissue damage. This hypothesis was supported by a case-control study that identified a specific TNF-a polymorphism more frequently in male smokers with chronic bronchitis than in randomly sampled schoolchildren or in age-, sex-, and smoking-matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/51\">",
"       51",
"      </a>",
"      ]. Data also exist that argue against the hypothesis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/48\">",
"       48",
"      </a>",
"      ]. In another case-control study, the same TNF-a polymorphism was not more common in patients with COPD, compared to healthy controls and asymptomatic smokers or former smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/52\">",
"       52",
"      </a>",
"      ]. In addition, anti-TNF-a antibody (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ) conferred no benefit to patients with moderate to severe COPD in a randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Microsomal epoxide hydrolase &mdash; Microsomal epoxide hydrolase reduces highly reactive epoxide intermediates generated by smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/54\">",
"       54",
"      </a>",
"      ]. Decreased function of microsomal epoxide hydrolase may predispose individuals to oxidative injury and subsequent COPD. This hypothesis is supported by a case-control study that compared patients with undifferentiated COPD or emphysema to controls with lung cancer or asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/55\">",
"       55",
"      </a>",
"      ]. Genotypes associated with decreased activity of microsomal epoxide hydrolase were found more often in patients with COPD and emphysema than in controls. Arguing against this hypothesis, a case-control study from Japan found that the frequency of genotypes associated with decreased activity of microsomal epoxide hydrolase was similar in patients with COPD and controls [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transforming growth factor beta 1 &mdash; Transforming growth factor beta is a member of a large superfamily of polypeptides involved in cellular growth, differentiation, and activation. SNPs of the gene encoding transforming growth factor beta 1 have been associated with development of COPD in smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/48,57,58\">",
"       48,57,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leptin receptor &mdash; In addition to a role in appetite suppression, leptin may have a role in systemic inflammatory responses, such as that related to cigarette smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/59\">",
"       59",
"      </a>",
"      ]. Several SNPs of the leptin receptor (LEPR) gene are associated with lung function decline among current and former smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ATP dependent helicase XRCC5 &mdash; Based on data from genomewide association studies, a region on chromosome 2q was suspected as the locus of a COPD susceptibility gene. Genotyping of SNPs in that region has identified the ATP dependent helicase XRCC5 as a potential susceptibility gene for COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antioxidant related enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic variation in antioxidant enzyme function or regulation may affect risk for COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/61\">",
"     61",
"    </a>",
"    ]. In particular, the genes for glutathione S-transferases P1 and M1, glutamate cysteine ligase, and superoxide dismutase appear to be involved. Gene association studies are not available for some other antioxidant enzymes (eg, thioredoxin, gamma-glutamyl transferase) that may turn out to be important.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glutathione S-transferases &ndash; Glutathione S-transferase P1 (GSTP1) aids in the detoxification of a number of substances that are found in cigarette smoke. Decreased glutathione S-transferase P1 activity due to genetic polymorphisms may increase the frequency of COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/54,62,63\">",
"       54,62,63",
"      </a>",
"      ]. Several case-control studies have identified a specific polymorphism in exon 5 (Ile105Val) that is more common among persons with COPD than controls [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/62,64\">",
"       62,64",
"      </a>",
"      ]. Homozygous deletion of glutathione S-transferase M1 (GSTM1) has been associated with increased COPD risk in some, but not all studies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/48,54,61,64\">",
"       48,54,61,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glutamate cysteine ligase &ndash; Glutamate cysteine ligase (GCL) is one of the three enzymes that relate to glutathione synthesis. Genetic variants in the promoter region and in the catalytic subunit that cause decreased glutathione levels have been associated with and increase risk of COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/61,65\">",
"       61,65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Metalloproteinase dysregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Matrix metalloproteinases (MMPs) are a family of zinc-dependent enzymes that degrade extracellular matrix proteins. The activity of MMPs is regulated by tissue inhibitors of metalloproteinase (TIMPs). Numerous observational studies have demonstrated an association between COPD and abnormal activity of certain MMP or TIMP subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study compared the bronchoalveolar lavage fluid of patients with emphysema to normal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/67\">",
"       67",
"      </a>",
"      ]. Patients with emphysema had increased MMP-1 (collagenase-1) expression and absent MMP-12 (macrophage elastase) activity [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sputum from patients with asthma and COPD has increased MMP-2 (gelatinase A), MMP-9 (gelatinase B), MMP-8 (Collagenase 2), and TIMP-1 activity, compared to controls [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/68,70\">",
"       68,70",
"      </a>",
"      ]. In addition, patients with stable COPD have an increased concentration of serum TIMP-1, compared to controls and patients with stable asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationships among MMPs, TIMPs, and COPD are an area of ongoing research, with MMP inhibitors under investigation as therapeutic agents for COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/66,72,73\">",
"     66,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Excess elastase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility that excess elastase contributes to COPD is suggested by two principal observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premature emphysema is associated with deficiency of alpha-1 antitrypsin, an inhibitor of neutrophil elastase. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Macrophage elastase-deficient mice do not develop emphysema despite intense, long-term exposure to cigarette smoke [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/74\">",
"       74",
"      </a>",
"      ]. This is true even if excess inflammatory cells are attracted to the lung with exogenously administered monocyte chemoattractant protein-1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RISK REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the clinical risk factors for chronic obstructive pulmonary disease (COPD) can be modified. However, it is difficult to directly measure the impact of risk factor modification on the incidence of COPD because of the extended duration between exposure to the risk factor and the onset of measurable airway obstruction. Studies need to be conducted over several decades for direct measurement.",
"   </p>",
"   <p>",
"    As an alternative approach, most studies determine the rate of lung function decline and use it as an indirect measure of the risk of developing COPD. The goal of risk factor modification is to mitigate lung function decline, since patients with increased lung function decline are more likely to develop COPD. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Lung function'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Indirect evidence suggests that smoking cessation has the greatest impact on preventing COPD. Physical activity and avoidance of inhalational exposures may also reduce the incidence of COPD. Anti-inflammatory therapy and antioxidant therapy have been studied, but appear to have minimal impact on the development of COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking cessation reduces the accelerated decline in lung function that is associated with smoking, which decreases the likelihood that COPD will develop [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/8,75,76\">",
"     8,75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated by a retrospective cohort study (n=8045) that found the incidence of COPD over 25 years was less among patients who had never smoked or quit smoking than among patients who continued to smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/8\">",
"     8",
"    </a>",
"    ]. Specifically, the incidence of COPD among never smokers, smokers who quit prior to the study, smokers who quit during the initial five years of the study, smokers who quit 5 to 15 years into the study, and smokers who quit 15 to 25 years into the study was 4, 12, 5, 14, and 24 percent, respectively among men. The incidence was 9, 11, 20, 25, 29, and 31 percent, respectively, among women.",
"   </p>",
"   <p>",
"    Additional benefits of smoking cessation, as well as risks and approaches are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Exposure avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction of environmental exposure to particulate matter, dusts, gases, fumes, or organic antigens is associated with slower lung function decline, but to a much smaller degree than smoking cessation.",
"   </p>",
"   <p>",
"    This was demonstrated by a retrospective cohort study (n = 9651), which found that decreased particulate matter concentration was associated with a small reduction of the annual rate of decline of the forced expiratory volume in one second (FEV1) over 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/77\">",
"     77",
"    </a>",
"    ]. Specifically, a 10 mcg per m3 annual decrease in the concentration of particulate matter was associated with a 3 mL reduction of the annual decrease of FEV1. This effect is small and of limited clinical relevance to individual patients, but may have public health relevance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of strategies are available to reduce the burden of inhaled particles and gases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Implement, monitor, and enforce strict control of airborne exposure in the workplace",
"     </li>",
"     <li>",
"      Initiate intensive and continuing education of workers, managers, clinicians, and legislators",
"     </li>",
"     <li>",
"      Promote smoking cessation since smoking aggravates exposure to other particles and gases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical activity may mitigate lung function decline in active smokers. In a retrospective cohort study, 6790 volunteers were followed for a median duration of 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/79\">",
"     79",
"    </a>",
"    ]. Active smokers with a moderate to high level of physical activity were less likely to develop COPD than active smokers with a low level of physical activity (OR 0.77, 95% CI 0.61-0.97). Additional studies are necessary before physical activity can be recommended as a means of decreasing the incidence of COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anti-inflammatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that increased airway responsiveness is a risk factor for COPD led to the hypothesis that antiinflammatory therapy may mitigate accelerated lung function decline.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhaled glucocorticoids &mdash; The use of inhaled glucocorticoids in young adults to prevent the onset of COPD has not been studied. However, the impact of inhaled glucocorticoids on lung function decline in patients with established COPD has been extensively studied and is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5463?source=see_link\">",
"       \"Role of inhaled glucocorticoid therapy in stable COPD\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Statins &mdash; Statins or HMG CoA reductase (hydroxymethylglutaryl CoA reductase) inhibitors are used for their lipid lowering characteristics, but also appear to have antiinflammatory properties [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/80\">",
"       80",
"      </a>",
"      ]. In a systematic review (nine studies), statins had a beneficial effect on various COPD outcomes, such as exacerbation rate, COPD-related intubation rate, exercise capacity and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/81\">",
"       81",
"      </a>",
"      ]. However, due to methodologic problems (eg, retrospective design, population-based analysis), prospective studies are needed to confirm these findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of alternative anti-inflammatory therapies (eg, nonsteroidal anti-inflammatory drugs, systemic glucocorticoids) has not been studied in relevant patient populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of antioxidant therapy (eg, N-acetylcysteine) on accelerated lung function decline was studied in response to observations that antioxidant deficiency may be a risk factor for COPD. The trial randomly assigned 50 patients with COPD to receive N-acetylcysteine or placebo for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/82\">",
"     82",
"    </a>",
"    ]. The yearly rate of lung function decline was similar in both groups. While N-acetylcysteine does not appear to impact lung function decline, it may reduce the frequency of exacerbations and improve symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6089/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/48/15107?source=see_link\">",
"       \"Patient information: Chronic bronchitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/52/14148?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic obstructive pulmonary disease (COPD) results from complex interactions between clinical and molecular (ie, genetic) risk factors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definite or possible risk factors for COPD include inhalational exposure (eg, smoking), increased airway responsiveness, atopy, and antioxidant deficiency. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Molecular risk factors for COPD include a variety of gene polymorphisms, antioxidant related enzyme dysfunction, metalloproteinase dysregulation, and abnormalities that cause excess elastase. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Molecular risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some of the clinical risk factors for COPD can be modified, thereby reducing the rate of lung function decline. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Risk reduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend smoking cessation for nearly all smokers (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). One of the benefits of smoking cessation is a markedly decreased risk of COPD. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Smoking cessation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT using N-acetylcysteine for the prevention of COPD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'N-acetylcysteine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Updated 2007. Global Initiative for Chronic Obstructive Lung Disease (GOLD). www.goldcopd.org (Accessed on January 08, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/2\">",
"      Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/3\">",
"      de Marco R, Accordini S, Marcon A, et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 2011; 183:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/4\">",
"      Perret JL, Dharmage SC, Matheson MC, et al. The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age. Am J Respir Crit Care Med 2013; 187:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/5\">",
"      Tager IB, Speizer FE. Risk estimates for chronic bronchitis in smokers: a study of male-female differences. Am Rev Respir Dis 1976; 113:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/6\">",
"      Xu X, Weiss ST, Rijcken B, Schouten JP. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur Respir J 1994; 7:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/7\">",
"      Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J 1976; 2:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/8\">",
"      L&oslash;kke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/9\">",
"      van Durme YM, Verhamme KM, Stijnen T, et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest 2009; 135:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/10\">",
"      Celedon JC, Speizer FE, Drazen JM, et al. Bronchodilator responsiveness and serum total IgE levels in families of probands with severe early-onset COPD. Eur Respir J 1999; 14:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/11\">",
"      Tan WC, Lo C, Jong A, et al. Marijuana and chronic obstructive lung disease: a population-based study. CMAJ 2009; 180:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/12\">",
"      Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/13\">",
"      Frew AJ, Kennedy SM, Chan-Yeung M. Methacholine responsiveness, smoking, and atopy as risk factors for accelerated FEV1 decline in male working populations. Am Rev Respir Dis 1992; 146:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/14\">",
"      O'Connor GT, Sparrow D, Weiss ST. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary-function decline: the Normative Aging Study. Am J Respir Crit Care Med 1995; 152:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/15\">",
"      Rijcken B, Schouten JP, Xu X, et al. Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. Am J Respir Crit Care Med 1995; 151:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/16\">",
"      Tracey M, Villar A, Dow L, et al. The influence of increased bronchial responsiveness, atopy, and serum IgE on decline in FEV1. A longitudinal study in the elderly. Am J Respir Crit Care Med 1995; 151:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/17\">",
"      Brutsche MH, Downs SH, Schindler C, et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006; 61:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/18\">",
"      O'Connor GT, Sparrow D, Weiss ST. The role of allergy and nonspecific airway hyperresponsiveness in the pathogenesis of chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/19\">",
"      Agnati LF, Zoli M, Biagini G, Fuxe K. Neuronal plasticity and ageing processes in the frame of the 'Red Queen Theory'. Acta Physiol Scand 1992; 145:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/20\">",
"      Korn RJ, Dockery DW, Speizer FE, et al. Occupational exposures and chronic respiratory symptoms. A population-based study. Am Rev Respir Dis 1987; 136:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/21\">",
"      Oxman AD, Muir DC, Shannon HS, et al. Occupational dust exposure and chronic obstructive pulmonary disease. A systematic overview of the evidence. Am Rev Respir Dis 1993; 148:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/22\">",
"      Sunyer J, Zock JP, Kromhout H, et al. Lung function decline, chronic bronchitis, and occupational exposures in young adults. Am J Respir Crit Care Med 2005; 172:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/23\">",
"      Terho EO. Work-related respiratory disorders among Finnish farmers. Am J Ind Med 1990; 18:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/24\">",
"      Dalphin JC, Debieuvre D, Pernet D, et al. Prevalence and risk factors for chronic bronchitis and farmer's lung in French dairy farmers. Br J Ind Med 1993; 50:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/25\">",
"      Terho EO, Husman K, Vohlonen I. Prevalence and incidence of chronic bronchitis and farmer's lung with respect to age, sex, atopy, and smoking. Eur J Respir Dis Suppl 1987; 152:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/26\">",
"      Torres-Duque C, Maldonado D, P&eacute;rez-Padilla R, et al. Biomass fuels and respiratory diseases: a review of the evidence. Proc Am Thorac Soc 2008; 5:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/27\">",
"      Pope CA 3rd, Ezzati M, Dockery DW. Fine-particulate air pollution and life expectancy in the United States. N Engl J Med 2009; 360:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/28\">",
"      Zhou Y, Wang C, Yao W, et al. COPD in Chinese nonsmokers. Eur Respir J 2009; 33:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/29\">",
"      Hu G, Zhou Y, Tian J, et al. Risk of COPD from exposure to biomass smoke: a metaanalysis. Chest 2010; 138:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/30\">",
"      Andersen ZJ, Hvidberg M, Jensen SS, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med 2011; 183:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/31\">",
"      Mehta AJ, Miedinger D, Keidel D, et al. Occupational exposure to dusts, gases, and fumes and incidence of chronic obstructive pulmonary disease in the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults. Am J Respir Crit Care Med 2012; 185:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/32\">",
"      Kurmi OP, Semple S, Simkhada P, et al. COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis. Thorax 2010; 65:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/33\">",
"      Po JY, FitzGerald JM, Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax 2011; 66:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/34\">",
"      Gottlieb DJ, Sparrow D, O'Connor GT, Weiss ST. Skin test reactivity to common aeroallergens and decline of lung function. The Normative Aging Study. Am J Respir Crit Care Med 1996; 153:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/35\">",
"      Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 2000; 106:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/36\">",
"      Cantin A, Crystal RG. Oxidants, antioxidants and the pathogenesis of emphysema. Eur J Respir Dis Suppl 1985; 139:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/37\">",
"      Sanguinetti CM. Oxidant/antioxidant imbalance: role in the pathogenesis of COPD. Respiration 1992; 59 Suppl 1:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/38\">",
"      Nowak D, Piasecka G, Antczak A, Pietras T. Effect of ascorbic acid on hydroxyl radical generation by chemical, enzymatic and cellular systems. Importance for antioxidant prevention of pulmonary emphysema. Biomed Biochim Acta 1991; 50:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/39\">",
"      Wong PM, Lees AN, Louw J, et al. Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia. Eur Respir J 2008; 32:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/40\">",
"      Lam KB, Jiang CQ, Jordan RE, et al. Prior TB, smoking, and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest 2010; 137:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/41\">",
"      Barnes PJ. Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999; 54:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/42\">",
"      Silverman EK. Genetics of chronic obstructive pulmonary disease. Novartis Found Symp 2001; 234:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/43\">",
"      Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998; 157:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/44\">",
"      Marciniak SJ, Lomas DA. What can naturally occurring mutations tell us about the pathogenesis of COPD? Thorax 2009; 64:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/45\">",
"      Silverman EK, Mosley JD, Palmer LJ, et al. Genome-wide linkage analysis of severe, early-onset chronic obstructive pulmonary disease: airflow obstruction and chronic bronchitis phenotypes. Hum Mol Genet 2002; 11:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/46\">",
"      Silverman EK, Palmer LJ, Mosley JD, et al. Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet 2002; 70:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/47\">",
"      Palmer LJ, Celed&oacute;n JC, Chapman HA, et al. Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. Hum Mol Genet 2003; 12:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/48\">",
"      Smolonska J, Wijmenga C, Postma DS, Boezen HM. Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Crit Care Med 2009; 180:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/49\">",
"      Wilk JB, Shrine NR, Loehr LR, et al. Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care Med 2012; 186:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/50\">",
"      Soler Artigas M, Loth DW, Wain LV, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet 2011; 43:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/51\">",
"      Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997; 156:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/52\">",
"      Higham MA, Pride NB, Alikhan A, Morrell NW. Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease. Eur Respir J 2000; 15:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/53\">",
"      Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/54\">",
"      Cheng SL, Yu CJ, Chen CJ, Yang PC. Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD. Eur Respir J 2004; 23:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/55\">",
"      Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997; 350:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/56\">",
"      Takeyabu K, Yamaguchi E, Suzuki I, et al. Gene polymorphism for microsomal epoxide hydrolase and susceptibility to emphysema in a Japanese population. Eur Respir J 2000; 15:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/57\">",
"      Celed&oacute;n JC, Lange C, Raby BA, et al. The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004; 13:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/58\">",
"      Wu L, Chau J, Young RP, et al. Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 2004; 59:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/59\">",
"      Hansel NN, Gao L, Rafaels NM, et al. Leptin receptor polymorphisms and lung function decline in COPD. Eur Respir J 2009; 34:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/60\">",
"      Hersh CP, Pillai SG, Zhu G, et al. Multistudy fine mapping of chromosome 2q identifies XRCC5 as a chronic obstructive pulmonary disease susceptibility gene. Am J Respir Crit Care Med 2010; 182:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/61\">",
"      Bentley AR, Emrani P, Cassano PA. Genetic variation and gene expression in antioxidant related enzymes and risk of COPD: a systematic review. Thorax 2008; 63:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/62\">",
"      Ishii T, Matsuse T, Teramoto S, et al. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/63\">",
"      Yim JJ, Yoo CG, Lee CT, et al. Lack of association between glutathione S-transferase P1 polymorphism and COPD in Koreans. Lung 2002; 180:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/64\">",
"      He JQ, Connett JE, Anthonisen NR, et al. Glutathione S-transferase variants and their interaction with smoking on lung function. Am J Respir Crit Care Med 2004; 170:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/65\">",
"      Liu S, Li B, Zhou Y, et al. Genetic analysis of CC16, OGG1 and GCLC polymorphisms and susceptibility to COPD. Respirology 2007; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/66\">",
"      Churg A, Wright JL. Proteases and emphysema. Curr Opin Pulm Med 2005; 11:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/67\">",
"      Imai K, Dalal SS, Chen ES, et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 2001; 163:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/68\">",
"      Cataldo D, Munaut C, No&euml;l A, et al. MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000; 123:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/69\">",
"      Leco KJ, Waterhouse P, Sanchez OH, et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001; 108:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/70\">",
"      Vernooy JH, Lindeman JH, Jacobs JA, et al. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004; 126:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/71\">",
"      Higashimoto Y, Yamagata Y, Iwata T, et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J 2005; 25:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/72\">",
"      Mao JT, Tashkin DP, Belloni PN, et al. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest 2003; 124:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/73\">",
"      Cawston T, Carrere S, Catterall J, et al. Matrix metalloproteinases and TIMPs: properties and implications for the treatment of chronic obstructive pulmonary disease. Novartis Found Symp 2001; 234:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/74\">",
"      Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997; 277:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/75\">",
"      Postma DS, Burema J, Gimeno F, et al. Prognosis in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1979; 119:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/76\">",
"      Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/77\">",
"      Downs SH, Schindler C, Liu LJ, et al. Reduced exposure to PM10 and attenuated age-related decline in lung function. N Engl J Med 2007; 357:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/78\">",
"      Lippmann M. Health effects of airborne particulate matter. N Engl J Med 2007; 357:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/79\">",
"      Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med 2007; 175:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/80\">",
"      Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/81\">",
"      Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest 2009; 136:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/82\">",
"      Decramer M, Rutten-van M&ouml;lken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/83\">",
"      Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6089/abstract/84\">",
"      Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1443 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-422ACB6E1F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6089=[""].join("\n");
var outline_f5_60_6089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LUNG FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Airway responsiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Environmental exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Atopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antioxidant deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MOLECULAR RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gene polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antioxidant related enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Metalloproteinase dysregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Excess elastase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RISK REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Exposure avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anti-inflammatory therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1443\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1443|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/51/15166\" title=\"figure 1\">",
"      Change in FEV1 with aging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35351?source=related_link\">",
"      Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25398?source=related_link\">",
"      Outcome of infants with bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/48/15107?source=related_link\">",
"      Patient information: Chronic bronchitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/52/14148?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5463?source=related_link\">",
"      Role of inhaled glucocorticoid therapy in stable COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_60_6090="Epidemiology of and risk factors for nephrolithiasis in children";
var content_f5_60_6090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of and risk factors for nephrolithiasis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6090/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6090/contributors\">",
"     Jodi Smith, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6090/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6090/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/60/6090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/60/6090/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/60/6090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrolithiasis is increasingly recognized in children. The epidemiology and etiology of nephrolithiasis in children will be reviewed here. The clinical manifestations, diagnosis, acute management, and prevention of recurrence are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13623?source=see_link\">",
"     \"Clinical features and diagnosis of nephrolithiasis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38552?source=see_link\">",
"     \"Acute management of nephrolithiasis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/62/19432?source=see_link\">",
"     \"Prevention of recurrent nephrolithiasis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to adult nephrolithiasis, the incidence of renal stones in children varies worldwide with the highest incidence occurring in endemic areas, such as in Turkey and Thailand.",
"   </p>",
"   <p>",
"    The incidence of nephrolithiasis is lower in children than in adults. As an example, in a population-based study from the United States (US) of patients over 10 years of age, adolescents between 10 and 19 years of age accounted for only 4 percent of the total episodes of nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/1\">",
"     1",
"    </a>",
"    ]. For the total population, the incidence of nephrolithiasis was 109 per 100,000 men per year and 36 per 100,000 women per year. The explanation for the lower pediatric incidence is unknown, but may be due in part to the higher concentrations of crystal formation inhibitors such as citrate and magnesium in the urine of children compared with adults [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A population study from Taiwan based on data from the National Health Insurance Research Database reported an annual incidence of 0.05 percent in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/4\">",
"     4",
"    </a>",
"    ]. The risk of nephrolithiasis was greater in children who lived in urban areas and those with urinary tract infection.",
"   </p>",
"   <p>",
"    The diagnosis of pediatric nephrolithiasis has increased over the past 25 years. This was illustrated in a population-based study of children who were younger than 18 years of age from a single county in Minnesota that reported a yearly increase in the incidence of nephrolithiasis over a 25-year period from 1984 to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/5\">",
"     5",
"    </a>",
"    ]. The age-gender adjusted pediatric nephrolithiasis rate rose from 7.2 to 14.5 per 100,000 person-years between the two time periods of 1984 to 1990 and 2003 to 2008. This increase was mainly due to an increased risk of stones in adolescents between 12 and 17 years of age (13 versus 36 per 100,000 person-years between the two time periods). In this cohort of 297 children with nephrolithiasis, the mean age was 13.2 years and 40 percent had a family history of stone disease. In this study, it remains uncertain whether there was a true increase in the risk of pediatric nephrolithiasis or if there was improvement in making the diagnosis of stone disease with the use of computerized tomography.",
"   </p>",
"   <p>",
"    In a study analyzing Pediatric Health Information System (PHIS) data from 41 freestanding US pediatric hospitals from 2002 to 2007, the diagnosis of nephrolithiasis was made in one case for every 685 pediatric hospitalizations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/6\">",
"     6",
"    </a>",
"    ]. Pediatric hospitalization for nephrolithiasis varied by region, and was most common in the North Central region of the country. More than half of the children were younger than 13 years of age, and stones were more commonly found in Caucasian children and rarely in African-American children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another report based on the PHIS data demonstrated that the proportion of hospitalizations due to pediatric nephrolithiasis rose from 18.4 per 100,000 admissions in 1999 to 57 per 100,000 in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/9\">",
"     9",
"    </a>",
"    ]. This trend is similar to the increased incidence in adult nephrolithiasis, which is thought to be due to changes in dietary habits (eg, increased intake of animal protein and sodium) and increased prevalence of obesity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369377009\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children do not have the strong male gender predominance as seen in adults with nephrolithiasis. Several studies do show a slightly higher prevalence in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/6,10-14\">",
"     6,10-14",
"    </a>",
"    ], whereas the previously mentioned Taiwanese study found a slightly higher (52 versus 48 percent) prevalence in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, gender distribution varied with age in children who were hospitalized for nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/15\">",
"     15",
"    </a>",
"    ]. Boys were more commonly affected in the first decade of life and girls in the second decade. This gender variation may reflect that boys are more likely to have obstructive urinary malformations resulting in nephrolithiasis that typically presents early, whereas there is an increase in the rate of urinary tract infections, another risk factor for renal stones, in postpubertal sexually active girls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369377016\">",
"    <span class=\"h2\">",
"     Stone composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon case series, the frequency of different stone composition in children is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calcium oxalate &ndash; 45 to 65 percent",
"     </li>",
"     <li>",
"      Calcium phosphate &ndash; 14 to 30 percent",
"     </li>",
"     <li>",
"      Struvite &ndash; 13 percent",
"     </li>",
"     <li>",
"      Cystine &ndash; 5 percent",
"     </li>",
"     <li>",
"      Uric acid &ndash; 4 percent",
"     </li>",
"     <li>",
"      Mixed or miscellaneous &ndash; 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with nephrolithiasis, an underlying risk factor is identified in 75 to 85 percent of affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. In most children, renal stones are associated with a urinary metabolic abnormality, urinary tract infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a structural renal or urinary tract abnormality as illustrated by the following retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/7,10-14,16\">",
"     7,10-14,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series from the Mayo Clinic, 221 children with nephrolithiasis were identified between 1965 and 1987 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/7\">",
"       7",
"      </a>",
"      ]. About half of the patients (n = 115) had an underlying metabolic abnormality that included hypercalciuria, hyperoxaluria, hyperuricosuria, and hypocitraturia in 49, 25, 8, and 5 patients, respectively. Stones associated with infection were found in 19 percent of patients. Of the 66 patients with structural anomalies of the kidney and urinary tract, 24 also had metabolic abnormalities and 26 had chronic infection.",
"     </li>",
"     <li>",
"      In a case series from the United Kingdom of 121 children with nephrolithiasis, 53 patients had a metabolic abnormality; 30 with hypercalciuria, 12 with cystinuria, four with primary hyperoxaluria and five with intermittent hyperoxaluria, one with hyperuricosuria, and one with hypercalcemia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/10\">",
"       10",
"      </a>",
"      ]. Thirty-six patients had stone disease associated with a urinary tract infection. There was no reported evaluation for underlying structural abnormalities or for urinary citrate excretion.",
"     </li>",
"     <li>",
"      In a case series from New York of 150 children with nephrolithiasis identified between 2000 and 2007, 39 of the 42 patients (93 percent) who underwent metabolic assessment, including 24-hour urine analysis, had identifiable metabolic abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/17\">",
"       17",
"      </a>",
"      ]. These included hypocitraturia in 26 patients, 14 with hypocalciuria, 4 with hyperoxaluria, and 1 with cystinuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     METABOLIC RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two mechanisms by which metabolic factors enhance stone formation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solute excess &ndash; High urinary concentrations of calcium, oxalate, uric acid, and cystine due to increased renal excretion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low urine volume cause solute excess. This leads to solute supersaturation and precipitation, and results in the formation of crystals, which may aggregate into a stone.",
"     </li>",
"     <li>",
"      Decrease levels of inhibitors of stone formation &ndash; Natural inhibitors of urinary stone formation include citrate, magnesium, and pyrophosphate. Low levels of these inhibitors, particularly hypocitraturia, are associated with nephrolithiasis in both adults and children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypercalciuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalciuria is the most common metabolic abnormality associated with pediatric urinary calculi [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. It is identified as the major contributing factor in at least half of the children with a metabolic cause for nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypercalciuria is defined as urinary calcium excretion rate that is greater than 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 24 hours in a child greater than two years of age, while ingesting a routine diet (",
"    <a class=\"graphic graphic_table graphicRef70589 \" href=\"UTD.htm?19/11/19643\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, urinary calcium excretion may normally be at this level during periods of rapid adolescent growth [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At times, it may be difficult to obtain a 24-hour sample. An alternative method of quantitative assessment is measurement of the total",
"    <span class=\"nowrap\">",
"     calcium/creatinine",
"    </span>",
"    ratio",
"    <span class=\"nowrap\">",
"     (mg/mg)",
"    </span>",
"    on a spot urine sample (",
"    <a class=\"graphic graphic_table graphicRef82389 \" href=\"UTD.htm?21/12/21708\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In particular, infants (one year of age or less) have higher urinary calcium excretion and lower urinary creatinine excretion. As a result, the normal urine",
"    <span class=\"nowrap\">",
"     calcium/creatinine",
"    </span>",
"    ratio for infants is higher than older children as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/20,21,23,24\">",
"     20,21,23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infants below six months of age &ndash; &lt;0.8",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      (2.25",
"      <span class=\"nowrap\">",
"       mmol/mmol)",
"      </span>",
"     </li>",
"     <li>",
"      Infants 6 to 12 months of age &ndash; &lt;0.6",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mmol/mmol)",
"      </span>",
"     </li>",
"     <li>",
"      Children two years of age or older &ndash; &lt;0.2 mg",
"      <span class=\"nowrap\">",
"       calcium/mg",
"      </span>",
"      creatinine (0.6",
"      <span class=\"nowrap\">",
"       mmol/mmol)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study from Turkey of 269 children, elevated urine",
"    <span class=\"nowrap\">",
"     calcium/creatinine",
"    </span>",
"    (ie, greater than 0.21",
"    <span class=\"nowrap\">",
"     mg/mg)",
"    </span>",
"    was a sensitive, but not specific, test for detecting hypercalciuria defined as a urinary calcium excretion greater than 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on a 24-hour urine sample [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/25\">",
"     25",
"    </a>",
"    ]. We suggest that a spot urine",
"    <span class=\"nowrap\">",
"     calcium/creatinine",
"    </span>",
"    ratio be used for screening for hypercalciuria. In patients with an elevated ratio, a 24-hour urine collection should be obtained to confirm the presence of hypercalciuria prior to initiation of treatment.",
"   </p>",
"   <p>",
"    Hypercalciuria may also cause nephrocalcinosis, a condition in which calcium salts precipitate out of solution within the renal tissue. Hematuria, dysuria, and urinary frequency can be seen in children with hypercalciuria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1127?source=see_link\">",
"     \"Evaluation of gross hematuria in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=see_link\">",
"     \"Evaluation of microscopic hematuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three mechanisms contribute to higher urinary calcium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased intestinal absorption (\"absorptive hypercalciuria\") in which there is an increase in intestinal calcium absorption resulting in excess serum calcium and high urinary calcium excretion.",
"     </li>",
"     <li>",
"      Increased renal losses (\"renal hypercalciuria\") in which there is a defect in renal tubular calcium reabsorption resulting in an increase in urinary calcium excretion.",
"     </li>",
"     <li>",
"      Increased bone resorption (\"resorptive hypercalciuria\") in which the source of the excess calcium is bone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both genetic and environmental factors can affect these mechanisms, thereby increasing urinary calcium excretion and the risk for nephrolithiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that many cases (and likely a majority of cases) of idiopathic hypercalciuria represent a complex interaction among many genes and environmental factors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Proposed specific involvement include genes that affect the calcium sensing receptor, calcium channels in the intestine and kidney, vitamin D receptor, intestinal oxalate exchangers, renal and bone resorption, and renal excretion of calcium, oxalate, and citrate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk factors for calcium stones in adults\", section on 'Family history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less commonly, a monogenic defect can cause hypercalciuria via any of the three physiologic mechanisms that results in nephrolithiasis or nephrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monogenic disorders that increase intestinal absorption of calcium include hypophosphatemia and absorptive hypercalciuria, Blue diaper syndrome, and congenital malabsorption disorders (ie, congenital",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"       lactase",
"      </a>",
"      deficiency, congenital sucrase-isomaltase deficiency, and",
"      <span class=\"nowrap\">",
"       glucose/galactose",
"      </span>",
"      malabsorption). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link&amp;anchor=H22#H22\">",
"       \"Etiology of hypercalcemia\", section on 'Congenital lactase deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monogenic disorders that impair renal tubular calcium reabsorption include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dent's disease, also referred to as X-linked recessive nephrolithiasis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link\">",
"       \"Dent's disease (X-linked recessive nephrolithiasis)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bartter syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"       \"Bartter and Gitelman syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wilson's disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H69500456#H69500456\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Other manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Glycogen storage disease type 1a (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=see_link&amp;anchor=H5#H5\">",
"       \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hereditary distal renal tubular acidosis (RTA) with identified mutations in either the basolateral chloride-bicarbonate cotransporter or in the apical hydrogen-ATPase (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H3#H3\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Distal (type 1) RTA'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=see_link\">",
"       \"Nephrolithiasis in renal tubular acidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"       \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link&amp;anchor=H8658123#H8658123\">",
"       \"Causes of hypomagnesemia\", section on 'Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"       \"Causes of hypomagnesemia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monogenic disorders that increase bone absorption include multiple endocrine neoplasia type 1 syndrome with hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/36\">",
"       36",
"      </a>",
"      ], and McCune-Albright syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"       \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following environmental factors can increase urinary calcium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/16,29-32\">",
"     16,29-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dehydration due to exertion or environmental conditions without adequate fluid replacement resulting in decreased urine volume.",
"     </li>",
"     <li>",
"      Immobilization with increased bone resorption [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medications such as loop diuretics, which increase calcium renal excretion (especially in neonates), and glucocorticoids, which increase bone resorption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26356?source=see_link\">",
"       \"Nephrocalcinosis in neonates\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excessive amounts of vitamin D.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of calcium, routine dietary vitamin D supplementation, and other solutes as risk factors in renal stone formation is unclear and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H15#H15\">",
"     \"Risk factors for calcium stones in adults\", section on 'Dietary risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary forms of hypercalciuria include hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/36\">",
"     36",
"    </a>",
"    ], chronic metabolic acidosis in association with hypocitraturia, hypercalcemia from any cause, and hypophosphatemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Hypocitraturia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"     \"Causes of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hyperoxaluria and oxalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case series of pediatric nephrolithiasis, hyperoxaluria is detected in 10 to 20 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. It is defined as a urinary oxalate excretion rate that is greater than 50",
"    <span class=\"nowrap\">",
"     mg/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    per 24 hours (",
"    <a class=\"graphic graphic_table graphicRef70589 \" href=\"UTD.htm?19/11/19643\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/20\">",
"     20",
"    </a>",
"    ]. An alternative method of quantitative assessment is measurement of the total",
"    <span class=\"nowrap\">",
"     oxalate/creatinine",
"    </span>",
"    ratio on a spot urine sample as follows (",
"    <a class=\"graphic graphic_table graphicRef82389 \" href=\"UTD.htm?21/12/21708\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients below six months of age &ndash; &lt;0.3",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      (0.06",
"      <span class=\"nowrap\">",
"       mmol/mmol)",
"      </span>",
"     </li>",
"     <li>",
"      Patients from six months to four years of age &ndash; &lt;0.15",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      (0.04",
"      <span class=\"nowrap\">",
"       mmol/mmol)",
"      </span>",
"     </li>",
"     <li>",
"      Patients greater than four years of age &ndash; &le;0.1",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      (0.03",
"      <span class=\"nowrap\">",
"       mmol/mmol)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Idiopathic hyperoxaluria is the most commonly diagnosed cause for children with oxalate stones. It often occurs in conjunction with hypercalciuria resulting in calcium oxalate crystals and stones (",
"    <a class=\"graphic graphic_picture graphicRef65169 graphicRef67694 \" href=\"UTD.htm?14/28/14788\">",
"     picture 1A-B",
"    </a>",
"    ). The underlying pathogenesis of idiopathic hyperoxaluria is unknown. It has been proposed that affected patients have increased urinary oxalate excretion because of increased oxalate production or enhanced gastrointestinal oxalate absorption.",
"   </p>",
"   <p>",
"    Other causes of hyperoxaluria include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary hyperoxaluria &ndash; Primary hyperoxaluria type I and II, rare autosomal disorders, are characterized by enhanced conversion of glyoxalate to poorly soluble oxalate resulting in increased serum oxalate and hyperoxaluria. These disorders are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"       \"Primary hyperoxaluria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fat malabsorption &ndash; Children with fat malabsorption may have an enhanced enteric absorption of oxalate. Excess fatty acid binds calcium resulting in less available calcium to combine with oxalate, and thus, more free oxalate is absorbed. Children with inflammatory bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/38\">",
"       38",
"      </a>",
"      ], extensive bowel resection, pancreatitis, and cystic fibrosis are at risk for hyperoxaluria and nephrolithiasis. In addition,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"       Orlistat",
"      </a>",
"      , a new antiobesity agent that inhibits gastrointestinal lipase, causes secondary hyperoxaluria [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H7#H7\">",
"       \"Risk factors for calcium stones in adults\", section on 'Hyperoxaluria'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689078#H12689078\">",
"       \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Malabsorption'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H14#H14\">",
"       \"Chronic complications of the short bowel syndrome in children\", section on 'Hyperoxaluria'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In these patients, the degree of hyperoxaluria is dependent on the dietary intake of oxalate. Urinary oxalate excretion can be reduced by decreasing dietary oxalate, eating a low-fat diet, adding dietary calcium supplements, and increasing fluid intake.",
"     </li>",
"     <li>",
"      Excessive oxalate ingestion &ndash; Ethylene glycol, ascorbic acid, and methoxyflurane are metabolized to form oxalate. Excessive ingestions of these products result in increased serum oxalate and hyperoxaluria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperuricosuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperuricosuria is detected in 2 to 8 percent of children with nephrolithiasis. Determining whether uric acid excretion is abnormally elevated in children can be challenging. Uric acid excretion is highest in infants and remains high in children until adolescence when values decrease to adult values. In infants, the normal urinary uric acid excretion is so high that crystals may precipitate in the diaper and be misidentified as blood (",
"    <a class=\"graphic graphic_picture graphicRef61827 graphicRef73642 \" href=\"UTD.htm?23/39/24177\">",
"     picture 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65328 \" href=\"UTD.htm?38/56/39808\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Reference values that are age-specific are available, however, for children three years of age or greater, normal uric acid excretion adjusted for glomerular filtration rate (GFR) is constant at a value less than 0.56",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.03",
"    <span class=\"nowrap\">",
"     mmol/dL)",
"    </span>",
"    based upon a random urine sample (",
"    <a class=\"graphic graphic_table graphicRef82389 \" href=\"UTD.htm?21/12/21708\">",
"     table 2",
"    </a>",
"    ). This value is calculated using the following equation, where UCr and PCr are the urine and plasma creatinine concentrations, respectively:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Urine uric acid &nbsp; x &nbsp; PCr",
"    <br/>",
"    &nbsp; &nbsp;Uric",
"    <span class=\"nowrap\">",
"     acid/GFR,",
"    </span>",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    &nbsp; &nbsp;= &nbsp; &nbsp; --------------------",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;UCr",
"   </p>",
"   <p>",
"    Increased urinary excretion of uric acid can result from either enhanced renal excretion or increased production of uric acid.",
"   </p>",
"   <p>",
"    Idiopathic hyperuricosuria is thought to be due to a defect in renal tubular uric acid excretion and is often seen in conjunction with hypercalciuria. It is also frequently present in families and is generally asymptomatic. However, in some families, formation of uric acid stones occurs, usually in individuals with constantly acidic urine.",
"   </p>",
"   <p>",
"    In childhood, pure uric stones are uncommon and are generally due to overproduction of uric acid due to tumor lysis syndrome, lymphoproliferative and myeloproliferative disorders, or rare genetic disorders such as Lesch-Nyhan (hypoxanthine-guanine phosphoribosyl transferase deficiency), and glycogen storage diseases. In addition, a high dietary intake of purines or hemolysis has been associated with uric acid nephrolithiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H25#H25\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Lesch-Nyhan syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=see_link\">",
"     \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28596?source=see_link\">",
"     \"Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of these conditions can also lead to acute renal failure due to precipitation of uric acid within the renal tubules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link&amp;anchor=H2#H2\">",
"     \"Uric acid renal diseases\", section on 'Acute uric acid nephropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cystinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystine stones account for 5 percent of pediatric renal calculi and are caused by cystinuria, an autosomal recessive disorder of renal tubular transport. Cystinuria is characterized by excessive excretion of the dibasic amino acids cystine, arginine, lysine, and ornithine. It appears to be caused by mutations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genomic rearrangements in two genes, SLC3A1 and SLC7A9. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"     \"Cystine stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, normal urinary cystine excretion rates are less than 60 mg of",
"    <span class=\"nowrap\">",
"     cystine/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    body surface area (BSA) per day (",
"    <a class=\"graphic graphic_table graphicRef70589 \" href=\"UTD.htm?19/11/19643\">",
"     table 1",
"    </a>",
"    ). Patients with cystinuria often excrete more than 400",
"    <span class=\"nowrap\">",
"     mg/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    BSA per day and patients with nonspecific proximal renal tubule aminoaciduria may excrete as much as 200 mg",
"    <span class=\"nowrap\">",
"     cystine/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    BSA per day. An alternative method of quantitative assessment is measurement of the total",
"    <span class=\"nowrap\">",
"     cystine/creatinine",
"    </span>",
"    ratio",
"    <span class=\"nowrap\">",
"     (mg/mg)",
"    </span>",
"    on a spot urine sample, which is normally less than 0.02",
"    <span class=\"nowrap\">",
"     mg/mg",
"    </span>",
"    (0.01",
"    <span class=\"nowrap\">",
"     mmol/mmol)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82389 \" href=\"UTD.htm?21/12/21708\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The colorless, flat, hexagonal cystine crystals found in the urinary sediment are diagnostic, but are only identified in 20 to 25 percent of individuals with this disorder (",
"    <a class=\"graphic graphic_picture graphicRef56834 \" href=\"UTD.htm?2/10/2208\">",
"     picture 4",
"    </a>",
"    ). Recurrent nephrolithiasis appears to be only manifestation of cystinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypocitraturia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Citrate is an inhibitor of calcium oxalate and calcium phosphate crystallization. In adult patients with idiopathic nephrolithiasis, hypocitraturia is a frequent finding. Hypocitraturia has also been reported in 10 percent of children with renal calculi [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/40\">",
"     40",
"    </a>",
"    ]. In one study, citrate excretion was lower in 78 children with calcium stones compared with a control group of 24 healthy nonstone forming children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Citrate excretion is greater in children than adults. In children, hypocitraturia is defined as a urinary citrate excretion rate that is less than 400",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    of creatinine in a 24-hour urine collection (",
"    <a class=\"graphic graphic_table graphicRef70589 \" href=\"UTD.htm?19/11/19643\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Citrate combines with calcium in the tubular lumen to form a nondissociable but soluble complex resulting in less free calcium available to combine with oxalate. Citrate also appears to inhibit crystal agglomeration, in which individual calcium oxalate crystals combine to form a stone.",
"   </p>",
"   <p>",
"    Children with chronic metabolic acidosis have an increased risk of nephrolithiasis. In these patients, because of enhanced proximal renal tubular citrate reabsorption, citrate excretion is decreased, leading to stone formation. Chronic diarrhea (ie, cystic fibrosis), administration of carbonic anhydrase inhibitors (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/43\">",
"     43",
"    </a>",
"    ]), and renal tubular acidosis (RTA) including acquired forms due to medications (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ) or recreational drugs (eg, toluene exposure from glue sniffing) are associated with chronic metabolic acidosis and nephrolithiasis.",
"   </p>",
"   <p>",
"    Although the cause of idiopathic hypocitraturia is unknown, proposed etiologies include ingestion of a high protein diet and polygenetic factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk factors for calcium stones in adults\", section on 'Hypocitraturia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Melamine exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melamine is a synthetic product used to form resins with formaldehyde and is found in a variety of products in which resin-based coatings are used. It is not intended for human or animal consumption. In experimental animal models, chronic melamine exposure resulted in the development of kidney and bladder stones, and possibly transitional cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/44\">",
"     44",
"    </a>",
"    ]. Analysis of the calculi from animal studies demonstrated equimolar amounts of melamine and uric acid, or melamine and cyanuric acid accounting for 60 to 80 percent of the stone weight [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/45\">",
"     45",
"    </a>",
"    ]. The stones are not radiopaque and therefore not seen on plain films; however, they are easily visualized by abdominal ultrasonography or computed tomography.",
"   </p>",
"   <p>",
"    Increased melamine exposure has been linked to urolithiasis in both children and adults. This risk was highlighted by the 2008 melamine-tainted baby formula in China that resulted in over 50,000 affected infants, including 13,000 who were hospitalized, and six deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Acute renal failure (ARF) due to urinary obstruction was reported in 104 children by China's Ministry of Health; however, reports from the provinces suggested that the number of cases of ARF approached 10,000. In a follow-up study of 25 patients with acute obstructive renal failure, renal function returned to normal in all patients by 17 months after hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/48\">",
"     48",
"    </a>",
"    ]. All calculi were expelled in two-thirds of patients within three months, 90 percent in six months, and 95 percent in nine months.",
"   </p>",
"   <p>",
"    Several retrospective studies have shown that infants with exposure to formula with a high melamine content (&gt;500 ppm) were most likely to develop nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. However, nephrolithiasis was also observed in patients with either exposure to formula with moderate (&lt;150 ppm) or low content (6.2 to 17 ppm). In most patients, there was a lack of urinary symptoms and abnormalities. In these studies, ultrasonographic evaluation was the main imaging study used to make the diagnosis of melamine-associated renal stone. However, the available data suggest that ultrasound screening for melamine-associated stones should be reserved only for individuals who have been exposed to products with high melamine concentration exceeding a minimum value of 150 ppm.",
"   </p>",
"   <p>",
"    Follow-up studies showed that nephrolithiasis resolved in most patients with conservative therapy (eg, increased fluid intake, urine alkalinization, and diuresis) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/52\">",
"     52",
"    </a>",
"    ]. In some cases, further interventions were undertaken including extracorporeal shock wave lithotripsy, retrograde ureteral catheterization, and other more invasive surgical procedures (ureteral lithectomy, percutaneous nephrostomy, or nephrolithotomy, and ureteroscopic lithotripsy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38552?source=see_link\">",
"     \"Acute management of nephrolithiasis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA) published guidelines that established a tolerable daily melamine intake of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, in an infant who weighs 5 kg, the greatest tolerable amount of melamine would be 2.5 mg per day, which is equivalent to an intake of 750 mL of formula with a concentration of melamine of 3.3",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (ppm). By comparison, the Sanlu product that has been incriminated in the cases in China had concentration of melamine that resulted in a 100-fold greater melamine intake than the suggested tolerable level [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, melamine exposure remains a potential source of nephrolithiasis, especially with the use of melamine tableware. Hot soup consumption using melamine bowls results in a continuous low-dose exposure to melamine, which has been associated with nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other metabolic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a wide range of disorders that result in urine solute excretion abnormalities that increase the risk of nephrolithiasis. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High animal protein diet &ndash; Diets with a high content of animal protein can result in high urinary excretion rates of uric acid, calcium, and oxalate, and low urinary excretion rate of citrate. These changes in urinary solute excretion may predispose the child to the formation of calcium oxalate crystals and stones.",
"     </li>",
"     <li>",
"      Ketogenic diet &ndash; Nephrolithiasis is reported in 3 to 10 percent of children treated with a ketogenic diet for management of their seizures disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/54-57\">",
"       54-57",
"      </a>",
"      ]. Urinary metabolic abnormalities include hypercalciuria, hyperuricosuria, and hypocitraturia. In patients with nephrolithiasis, the stone composition varies and includes calcium oxalate, uric acid, and ammonium urate, as well as mixed stones of calcium and uric acid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=see_link\">",
"       \"The ketogenic diet\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cystic fibrosis &ndash; Patients with cystic fibrosis have an increased risk of nephrolithiasis, most commonly due to calcium oxalate, and nephrocalcinosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. Although hyperuricosuria, hypercalciuria, and hypocitraturia can be present, hyperoxaluria due to enhanced enteric oxalate absorption is thought to be the primary contributor to stone formation. In addition, tubular dysfunction from cotrimoxazole and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"       ceftazidime",
"      </a>",
"      therapy may play a role in nephrolithiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Drugs &ndash; Many drugs alter solute excretion such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"       acetazolamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/3/24629?source=see_link\">",
"       allopurinol",
"      </a>",
"      , resulting in stone formation. A rare complication of allopurinol therapy is secondary xanthinuria and hypouricosuria. In contrast, stone formation due to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/39/28281?source=see_link\">",
"       indinavir",
"      </a>",
"      , a HIV protease inhibitor, is due to precipitation of the drug itself, which has a low solubility at a urine pH of 6.0 (",
"      <a class=\"graphic graphic_picture graphicRef70939 \" href=\"UTD.htm?21/23/21877\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link&amp;anchor=H11#H11\">",
"       \"HIV protease inhibitors\", section on 'Indinavir'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inborn errors of metabolism associated with nephrolithiasis include abnormalities in purine and pyrimidine metabolism, such as the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Adenine phosphoribosyl transferase deficiency, a rare inborn error of purine metabolism, is an autosomal recessive trait that is associated with radiopaque calculi composed of 2,8-dehydoxyadenine [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Xanthine oxidase deficiency, an autosomal disorder of purine metabolism, results in xanthine calculi in one-third of affected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/61\">",
"       61",
"      </a>",
"      ]. These patients have a low urinary excretion of uric acid.",
"     </li>",
"     <li>",
"      Orotic aciduria is a rare inborn error of pyrimidine metabolism that is recessively inherited. This disorder is characterized by an onset in early infancy, growth failure, developmental delay, hypochromic anemia, and excessive urinary excretion of orotic acid, an intermediary of uridine synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another inborn error of metabolism, alkaptonuria, is a disorder of tyrosine metabolism that is usually associated with nephrolithiasis in adulthood, but there are cases of renal calculi reported in childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link&amp;anchor=H19#H19\">",
"       \"Disorders of tyrosine metabolism\", section on 'Alkaptonuria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 20 to 25 percent of children with nephrolithiasis, urinary tract infection (UTI) is detected or there is a history of a UTI. Infection may be the primary cause of a stone or occur concomitantly with a underlying urinary metabolic abnormality or structural abnormality.",
"   </p>",
"   <p>",
"    Functional or anatomic obstruction of the urinary tract predisposes children to stasis and infection, which promote stone formation. Because boys are more likely to have obstructive uropathy, 80 percent of children with stones associated with infections are male. Infection-associated stones are usually detected before five years of age. All races are equally affected. Improvements in the detection and repair of obstructive uropathy have reduced the incidence of stones due to infections.",
"   </p>",
"   <p>",
"    Bacteria that produce the enzyme urease are strongly associated with pediatric nephrolithiasis and include Proteus, Providencia, Klebsiella, Pseudomonas, and enterococci. Urease breaks down urea to form ammonium and bicarbonate, which creates a favorable biochemical milieu for the formation of struvite stones (magnesium ammonium phosphate). Struvite stones, which can contain carbonate apatite, tend to branch, enlarge, and often fill the renal calyces, producing a \"staghorn\" appearance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62009 \" href=\"UTD.htm?42/7/43123\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72669 \" href=\"UTD.htm?20/47/21233\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of struvite stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, infections may also produce a soft radiolucent mucoid substance called \"matrix concretion\" that may calcify readily and account for the rapid formation of some infection-related calculi.",
"   </p>",
"   <p>",
"    Xanthogranulomatous pyelonephritis is a rare, severe chronic infection of the kidney that leads to renal parenchymal destruction and chronic inflammation characterized by lipid-laden macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. In 70 percent of affected children, obstruction is caused by renal calculi, resulting in a nonfunctioning or poorly functioning kidney. Nephrectomy or partial nephrectomy is often required to treat these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16804?source=see_link\">",
"     \"Xanthogranulomatous pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CONGENITAL/STRUCTURAL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case series of children with nephrolithiasis, structural abnormalities are reported in 10 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/7,68,69\">",
"     7,68,69",
"    </a>",
"    ]. Congenital and structural abnormalities that are accompanied by urinary stasis are associated with nephrolithiasis. Urinary stasis predisposes to crystal and stone formation.",
"   </p>",
"   <p>",
"    Renal and urinary tract abnormalities associated with urinary stasis and nephrolithiasis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medullary sponge disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=see_link&amp;anchor=H21853656#H21853656\">",
"       \"Medullary sponge kidney\", section on 'Kidney stones and nephrocalcinosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Autosomal dominant polycystic kidney disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link&amp;anchor=H5#H5\">",
"       \"Renal manifestations of autosomal dominant polycystic kidney disease\", section on 'Nephrolithiasis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ureteropelvic junction obstruction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=see_link\">",
"       \"Congenital ureteropelvic junction obstruction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Horseshoe kidney (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73581 \" href=\"UTD.htm?22/54/23393\">",
"       image 3",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28487?source=see_link&amp;anchor=H9#H9\">",
"       \"Renal ectopic and fusion anomalies\", section on 'Horseshoe kidney'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Bladder exstrophy",
"     </li>",
"     <li>",
"      Augmentation of the bladder &ndash; Patients who have surgically augmented bladders are at risk for nephrolithiasis, most commonly bladder stones composed of struvite [",
"      <a class=\"abstract\" href=\"UTD.htm?5/60/6090/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neurogenic bladder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/38/27234?source=see_link\">",
"       \"Patient information: Kidney stones in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary stones develop when there is precipitation of solutes because of urinary solute supersaturation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H2#H2\">",
"       \"Risk factors for calcium stones in adults\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An underlying risk factor is identified in 75 to 85 percent of children with nephrolithiasis. Predisposing conditions include a urinary metabolic abnormality, infection,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      structural abnormality of the kidney or urinary tract. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A urinary metabolic abnormality is identified in about 40 to 50 percent of children with nephrolithiasis. The most common disorder is hypercalciuria followed by hyperoxaluria, and hypocitraturia. Hyperuricosuria and cystinuria are less commonly seen in children with pediatric nephrolithiasis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Metabolic risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In 20 to 25 percent of children with nephrolithiasis, a urinary tract infection (UTI) is detected or there is a history of a UTI. Infection may be the primary cause of pediatric nephrolithiasis or occur concomitantly with underlying urinary metabolic abnormality or structural abnormality. Bacteria that produce the enzyme urease are strongly associated with pediatric nephrolithiasis and include Proteus, Providencia, Klebsiella, Pseudomonas, and enterococci. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Structural abnormalities are reported in 10 to 25 percent of children with nephrolithiasis. In these children, urinary stasis predisposes to crystal formation and stone formation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Congenital/structural abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/1\">",
"      Johnson CM, Wilson DM, O'Fallon WM, et al. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int 1979; 16:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/2\">",
"      Miyake O, Yoshimura K, Tsujihata M, et al. Possible causes for the low prevalence of pediatric urolithiasis. Urology 1999; 53:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/3\">",
"      Miyake O, Yoshimura K, Yoshioka T, et al. High urinary excretion level of citrate and magnesium in children: potential etiology for the reduced incidence of pediatric urolithiasis. Urol Res 1998; 26:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/4\">",
"      Huang WY, Chen YF, Chen SC, et al. Pediatric urolithiasis in Taiwan: a nationwide study, 1997-2006. Urology 2012; 79:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/5\">",
"      Dwyer ME, Krambeck AE, Bergstralh EJ, et al. Temporal trends in incidence of kidney stones among children: a 25-year population based study. J Urol 2012; 188:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/6\">",
"      Bush NC, Xu L, Brown BJ, et al. Hospitalizations for pediatric stone disease in United States, 2002-2007. J Urol 2010; 183:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/7\">",
"      Milliner DS, Murphy ME. Urolithiasis in pediatric patients. Mayo Clin Proc 1993; 68:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/8\">",
"      Stapleton FB, McKay CP, Noe HN. Urolithiasis in children: the role of hypercalciuria. Pediatr Ann 1987; 16:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/9\">",
"      Routh JC, Graham DA, Nelson CP. Epidemiological trends in pediatric urolithiasis at United States freestanding pediatric hospitals. J Urol 2010; 184:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/10\">",
"      Coward RJ, Peters CJ, Duffy PG, et al. Epidemiology of paediatric renal stone disease in the UK. Arch Dis Child 2003; 88:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/11\">",
"      Gearhart JP, Herzberg GZ, Jeffs RD. Childhood urolithiasis: experiences and advances. Pediatrics 1991; 87:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/12\">",
"      Diamond DA. Clinical patterns of paediatric urolithiasis. Br J Urol 1991; 68:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/13\">",
"      Perrone HC, dos Santos DR, Santos MV, et al. Urolithiasis in childhood: metabolic evaluation. Pediatr Nephrol 1992; 6:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/14\">",
"      Sarkissian A, Babloyan A, Arikyants N, et al. Pediatric urolithiasis in Armenia: a study of 198 patients observed from 1991 to 1999. Pediatr Nephrol 2001; 16:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/15\">",
"      Novak TE, Lakshmanan Y, Trock BJ, et al. Sex prevalence of pediatric kidney stone disease in the United States: an epidemiologic investigation. Urology 2009; 74:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/16\">",
"      Stapleton FB. Nephrolithiasis in children. Pediatr Rev 1989; 11:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/17\">",
"      Kalorin CM, Zabinski A, Okpareke I, et al. Pediatric urinary stone disease--does age matter? J Urol 2009; 181:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/18\">",
"      DeFoor W, Minevich E, Jackson E, et al. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol 2008; 179:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/19\">",
"      Bergsland KJ, Coe FL, White MD, et al. Urine risk factors in children with calcium kidney stones and their siblings. Kidney Int 2012; 81:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/20\">",
"      De Santo NG, Di Iorio B, Capasso G, et al. Population based data on urinary excretion of calcium, magnesium, oxalate, phosphate and uric acid in children from Cimitile (southern Italy). Pediatr Nephrol 1992; 6:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/21\">",
"      Kruse K, Kracht U, Kruse U. Reference values for urinary calcium excretion and screening for hypercalciuria in children and adolescents. Eur J Pediatr 1984; 143:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/22\">",
"      Chen YH, Lee AJ, Chen CH, et al. Urinary mineral excretion among normal Taiwanese children. Pediatr Nephrol 1994; 8:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/23\">",
"      Karl&eacute;n J, Aperia A, Zetterstr&ouml;m R. Renal excretion of calcium and phosphate in preterm and term infants. J Pediatr 1985; 106:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/24\">",
"      Sargent JD, Stukel TA, Kresel J, Klein RZ. Normal values for random urinary calcium to creatinine ratios in infancy. J Pediatr 1993; 123:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/25\">",
"      Koyun M, G&uuml;ven AG, Filiz S, et al. Screening for hypercalciuria in schoolchildren: what should be the criteria for diagnosis? Pediatr Nephrol 2007; 22:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/26\">",
"      Stapleton FB. Idiopathic hypercalciuria: association with isolated hematuria and risk for urolithiasis in children. The Southwest Pediatric Nephrology Study Group. Kidney Int 1990; 37:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/27\">",
"      Stapleton FB. Hematuria associated with hypercalciuria and hyperuricosuria: a practical approach. Pediatr Nephrol 1994; 8:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/28\">",
"      Garcia CD, Miller LA, Stapleton FB. Natural history of hematuria associated with hypercalciuria in children. Am J Dis Child 1991; 145:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/29\">",
"      Aladjem M, Barr J, Lahat E, Bistritzer T. Renal and absorptive hypercalciuria: a metabolic disturbance with varying and interchanging modes of expression. Pediatrics 1996; 97:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/30\">",
"      Coe FL, Bushinsky DA. Pathophysiology of hypercalciuria. Am J Physiol 1984; 247:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/31\">",
"      Pak CY. Physiological basis for absorptive and renal hypercalciurias. Am J Physiol 1979; 237:F415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/32\">",
"      Weisinger JR. New insights into the pathogenesis of idiopathic hypercalciuria: the role of bone. Kidney Int 1996; 49:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/33\">",
"      Srivastava T, Alon US. Pathophysiology of hypercalciuria in children. Pediatr Nephrol 2007; 22:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/34\">",
"      Moe OW, Bonny O. Genetic hypercalciuria. J Am Soc Nephrol 2005; 16:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/35\">",
"      Gambaro G, Vezzoli G, Casari G, et al. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 2004; 44:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/36\">",
"      Kollars J, Zarroug AE, van Heerden J, et al. Primary hyperparathyroidism in pediatric patients. Pediatrics 2005; 115:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/37\">",
"      Bergstrom WH. Hypercalciuria and hypercalcemia complicating immobilization. Am J Dis Child 1978; 132:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/38\">",
"      Hueppelshaeuser R, von Unruh GE, Habbig S, et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease. Pediatr Nephrol 2012; 27:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/39\">",
"      Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007; 49:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/40\">",
"      Miller LA, Stapleton FB. Urinary citrate excretion in children with hypercalciuria. J Pediatr 1985; 107:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/41\">",
"      Tekin A, Tekgul S, Atsu N, et al. A study of the etiology of idiopathic calcium urolithiasis in children: hypocitruria is the most important risk factor. J Urol 2000; 164:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/42\">",
"      Sch&auml;rer K, Manz F. Renal handling of citrate in children with various kidney disorders. Int J Pediatr Nephrol 1985; 6:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/43\">",
"      Welch BJ, Graybeal D, Moe OW, et al. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis 2006; 48:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/44\">",
"      Melnick RL, Boorman GA, Haseman JK, et al. Urolithiasis and bladder carcinogenicity of melamine in rodents. Toxicol Appl Pharmacol 1984; 72:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/45\">",
"      Ogasawara H, Imaida K, Ishiwata H, et al. Urinary bladder carcinogenesis induced by melamine in F344 male rats: correlation between carcinogenicity and urolith formation. Carcinogenesis 1995; 16:2773.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Melamine and cyanuric acid: Toxicity, preliminary risk assessment and guidance on levels in food. September 25, 2008. Available at: www.who.int/foodsafety/fs_management/Melamine.pdf (Accessed on January 27, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/47\">",
"      Parry J. China's tainted milk scandal spreads around world. BMJ 2008; 337:a1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/48\">",
"      Sun Q, Shen Y, Sun N, et al. Diagnosis, treatment and follow-up of 25 patients with melamine-induced kidney stones complicated by acute obstructive renal failure in Beijing Children's Hospital. Eur J Pediatr 2010; 169:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/49\">",
"      Guan N, Fan Q, Ding J, et al. Melamine-contaminated powdered formula and urolithiasis in young children. N Engl J Med 2009; 360:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/50\">",
"      Zhu SL, Li JH, Chen L, et al. Conservative management of pediatric nephrolithiasis caused by melamine-contaminated milk powder. Pediatrics 2009; 123:e1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/51\">",
"      Lam HS, Ng PC, Chu WC, et al. Renal screening in children after exposure to low dose melamine in Hong Kong: cross sectional study. BMJ 2008; 337:a2991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/52\">",
"      Panfeng S, Hong C, Zhongjin Y, et al. Management of pediatric urolithiasis induced by melamine-contaminated powdered formula (report of 619 cases). Urology 2011; 78:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/53\">",
"      Wu CF, Hsieh TJ, Chen BH, et al. A crossover study of noodle soup consumption in melamine bowls and total melamine excretion in urine. JAMA Intern Med 2013; 173:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/54\">",
"      Kielb S, Koo HP, Bloom DA, Faerber GJ. Nephrolithiasis associated with the ketogenic diet. J Urol 2000; 164:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/55\">",
"      Herzberg GZ, Fivush BA, Kinsman SL, Gearhart JP. Urolithiasis associated with the ketogenic diet. J Pediatr 1990; 117:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/56\">",
"      Furth SL, Casey JC, Pyzik PL, et al. Risk factors for urolithiasis in children on the ketogenic diet. Pediatr Nephrol 2000; 15:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/57\">",
"      Sharma S, Gulati S, Kalra V, et al. Seizure control and biochemical profile on the ketogenic diet in young children with refractory epilepsy--Indian experience. Seizure 2009; 18:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/58\">",
"      Hoppe B, Hesse A, Br&ouml;mme S, et al. Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis? Pediatr Nephrol 1998; 12:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/59\">",
"      B&ouml;hles H, Gebhardt B, Beeg T, et al. Antibiotic treatment-induced tubular dysfunction as a risk factor for renal stone formation in cystic fibrosis. J Pediatr 2002; 140:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/60\">",
"      Edvardsson V, Palsson R, Olafsson I, et al. Clinical features and genotype of adenine phosphoribosyltransferase deficiency in iceland. Am J Kidney Dis 2001; 38:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/61\">",
"      Carpenter TO, Lebowitz RL, Nelson D, Bauer S. Hereditary xanthinuria presenting in infancy with nephrolithiasis. J Pediatr 1986; 109:307.",
"     </a>",
"    </li>",
"    <li>",
"     Sadler L, Stapleton FB. Disorders of porphyrin, purine, and phyridimine metabolism. In: Current Pediatric Therapy, 15th ed, Burg FD, Ingelfinger JR, Wald ER (Eds), WB Saunders, Philadelphia 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/63\">",
"      Zibolen M, Srsnova K, Srsen S. Increased urolithiasis in patients with alkaptonuria in childhood. Clin Genet 2000; 58:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/64\">",
"      Samuel M, Duffy P, Capps S, et al. Xanthogranulomatous pyelonephritis in childhood. J Pediatr Surg 2001; 36:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/65\">",
"      Bing&ouml;l-Kololu M, Cift&ccedil;i AO, Senocak ME, et al. Xanthogranulomatous pyelonephritis in children: diagnostic and therapeutic aspects. Eur J Pediatr Surg 2002; 12:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/66\">",
"      Zugor V, Schott GE, Labanaris AP. Xanthogranulomatous pyelonephritis in childhood: a critical analysis of 10 cases and of the literature. Urology 2007; 70:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/67\">",
"      Hussein N, Osman Y, Sarhan O, et al. Xanthogranulomatous pyelonephritis in pediatric patients: effect of surgical approach. Urology 2009; 73:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/68\">",
"      VanDervoort K, Wiesen J, Frank R, et al. Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol 2007; 177:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/69\">",
"      Sternberg K, Greenfield SP, Williot P, Wan J. Pediatric stone disease: an evolving experience. J Urol 2005; 174:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/60/6090/abstract/70\">",
"      Fontaine E, Gagnadoux MF, Niaudet P, et al. Renal transplantation in children with augmentation cystoplasty: long-term results. J Urol 1998; 159:2110.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6112 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6090=[""].join("\n");
var outline_f5_60_6090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369377009\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369377016\">",
"      Stone composition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      METABOLIC RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypercalciuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hyperoxaluria and oxalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperuricosuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cystinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypocitraturia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Melamine exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other metabolic causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CONGENITAL/STRUCTURAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6112\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6112|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/7/43123\" title=\"diagnostic image 1\">",
"      KUB showing staghorn calculi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/47/21233\" title=\"diagnostic image 2\">",
"      CT scan showing large renal pelvic stone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/54/23393\" title=\"diagnostic image 3\">",
"      CT scan horseshoe kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6112|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/19/42302\" title=\"picture 1A\">",
"      Calcium oxalate crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/20/10561\" title=\"picture 1B\">",
"      Ca oxalate monohydrate crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/50/11040\" title=\"picture 2A\">",
"      Uric acid crystals in the urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/51/21309\" title=\"picture 2B\">",
"      Uric acid crystals under polarized light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/56/39808\" title=\"picture 3\">",
"      Urate crystals diaper",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/10/2208\" title=\"picture 4\">",
"      Cystine crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/23/21877\" title=\"picture 5\">",
"      Indinavir crystals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6112|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/11/19643\" title=\"table 1\">",
"      Normal urinary values children 24-hour urine collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/12/21708\" title=\"table 2\">",
"      Normal urinary solute value in children random urine collection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38552?source=related_link\">",
"      Acute management of nephrolithiasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=related_link\">",
"      Chronic complications of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13623?source=related_link\">",
"      Clinical features and diagnosis of nephrolithiasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26680?source=related_link\">",
"      Congenital ureteropelvic junction obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=related_link\">",
"      Cystine stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=related_link\">",
"      Dent's disease (X-linked recessive nephrolithiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1127?source=related_link\">",
"      Evaluation of gross hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=related_link\">",
"      Evaluation of microscopic hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=related_link\">",
"      Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=related_link\">",
"      Medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26356?source=related_link\">",
"      Nephrocalcinosis in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=related_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=related_link\">",
"      Pathogenesis and clinical manifestations of struvite stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/38/27234?source=related_link\">",
"      Patient information: Kidney stones in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28596?source=related_link\">",
"      Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/62/19432?source=related_link\">",
"      Prevention of recurrent nephrolithiasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28487?source=related_link\">",
"      Renal ectopic and fusion anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16804?source=related_link\">",
"      Xanthogranulomatous pyelonephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_60_6091="Yin Yang symptoms";
var content_f5_60_6091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Yin/Yang symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Yin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Yang",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue, drowsiness",
"       </td>",
"       <td>",
"        Restlessness, throws off covers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facial pallor",
"       </td>",
"       <td>",
"        Flushed complexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desires heat",
"       </td>",
"       <td>",
"        Likes cold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea/watery stools",
"       </td>",
"       <td>",
"        Constipation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Likes quiet, no desire to talk",
"       </td>",
"       <td>",
"        Noisy, loud mouthed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copious clear urine",
"       </td>",
"       <td>",
"        Dark, scanty urine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6091=[""].join("\n");
var outline_f5_60_6091=null;
var title_f5_60_6092="Etiology pediatric chest pain";
var content_f5_60_6092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of pediatric chest pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence, percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"       <td>",
"        21 to 45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Musculoskeletal",
"       </td>",
"       <td>",
"        15 to 31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperventilation/psychiatric",
"       </td>",
"       <td>",
"        0 to 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast related",
"       </td>",
"       <td>",
"        1 to 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory",
"       </td>",
"       <td>",
"        2 to 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        2 to 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac",
"       </td>",
"       <td>",
"        1 to 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *These ranges refer to the prevalence of chest pain etiology among children evaluated by a primary care provider, pediatric emergency medicine subspecialist, or cardiologist.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Selbst SM, Pediatrics 1985; 75:1068.",
"       </li>",
"       <li>",
"        Selbst SM, Ruddy RM, Clark BJ, et al., Pediatrics 1988; 82:319.",
"       </li>",
"       <li>",
"        Pantell RH, Goodman BW Jr, Pediatrics 1983; 71:881.",
"       </li>",
"       <li>",
"        Fyfe DA, Moodie DS, Clin Pediatr (Phila) 1984; 23:321.",
"       </li>",
"       <li>",
"        Selbst SM, Ruddy R, Clark BJ, Clin Pediatr (Phila) 1990; 29:374.",
"       </li>",
"       <li>",
"        Driscoll DJ, Glicklich LB, Gallen WJ, Pediatrics 1976; 57:648.",
"       </li>",
"       <li>",
"        Kocis KC, Pediatr Clin North Am 1999; 46:189.",
"       </li>",
"       <li>",
"        Tunaoglu FS, Olgunturk R, Akcabay S, Oguz D, Pediatr Cardiol 1995; 16:69.",
"       </li>",
"       <li>",
"        Anzai AK, Merkin TE, Am Fam Physician 1996; 53:1682.",
"       </li>",
"       <li>",
"        Zavaras-Angelidou KA, Weinhouse E, Nelson DB, Pediatr Emerg Care 1992; 8:189.",
"       </li>",
"       <li>",
"        Selbst SM, Pediatr Rev 1986; 8:56.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6092=[""].join("\n");
var outline_f5_60_6092=null;
var title_f5_60_6093="Dietary guidelines children";
var content_f5_60_6093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary guidelines for children older than one year",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A variety of nutrient-dense foods from the basic food groups (milk/milk products, meat/protein, grains, fruits/vegetables) should be offered each day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foods and beverages should contain or be prepared with little added salt, sugar, or caloric sweeteners.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 2 years: Fat and cholesterol intake are not restricted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 3 years: Fat should comprise 30 to 35 percent of total energy intake; saturated fats should be limited to &lt;10 percent of total energy intake, cholesterol should be limited to &lt;300 mg/day; intake of trans fats should be as low as possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 18 years: Fat should comprise 25 to 35 percent of total energy intake; fat intake should not be restricted to &lt;20 percent of total energy intake; saturated fats should be limited to &lt;10 percent of total energy intake, cholesterol should be limited to &lt;300 mg/day; intake of trans fats should be as low as possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Meat/protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Select and prepare meat, poultry, fish, and dried beans with as little fat as possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fruits and vegetables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A colorful variety of fruits and vegetables should be offered each day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whole fruit is preferred to fruit juice, but one-half of the recommended daily servings can be provided in the form of 100 percent fruit juice.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consumption of 100 percent fruit juice should be limited to 4 to 6 ounces in children aged 1 to 6 years and 8 to 12 ounces in children older than 7 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At least one-half of total grains consumed should be whole grains. When reading the label, \"whole grain\" should be the first ingredient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cow's milk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 2 years: At least 2 cups of whole milk per day (or equivalent products).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 8 years: At least 2 to 3 cups of fat-free or low-fat milk per day (or equivalent products).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;9 years: At least 3 cups of fat-free or low-fat milk per day (or equivalent products).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Beverages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plain, unflavored water is the preferred beverage for children, particularly when fluids are consumed outside of meals and snacks.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Committee on Nutrition American Academy of Pediatrics. Feeding the Child. In: Pediatric Nutrition Handbook, 6th ed, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.145.",
"       </li>",
"       <li>",
"        US Department of Health and Human Services. Dietary Guidelines for Americans, 2010.",
"        <a href=\"file://www.health.gov/dietaryguidelines/\" target=\"_blank\">",
"         file://www.health.gov/dietaryguidelines/",
"        </a>",
"        (Accessed on June 03, 2011).",
"       </li>",
"       <li>",
"        Gidding SS, Dennison BA, Birch LL, et al. Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. Circulation 2005; 112:2061.",
"       </li>",
"       <li>",
"        Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Available at:",
"        <a href=\"file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx\" target=\"_blank\">",
"         www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx",
"        </a>",
"        . Accessed on October 4, 2011.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6093=[""].join("\n");
var outline_f5_60_6093=null;
var title_f5_60_6094="Mechanism ANP BNP HF";
var content_f5_60_6094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Natriuretic peptides in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 274px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representation of the effects of elevated plasma atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in severe heart failure. ANP and BNP may increase (+) the rate of sodium excretion and reduce (-) the effects of the renin-angiotensin (RAS), sympathetic nervous systems (NS), and endothelin (ET)-1; the net effect of these actions is reduced preload and afterload. A similar elevation in inducible nitric oxide synthase (iNOS) is seen in humans with severe heart failure. These initially homeostatic mechanisms paradoxically contribute to the pathophysiology of the failing myocardium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baig M, Mahon N, McKenna WJ, et al. Am Heart J 1998; 135:S217. Copyright &copy; 1998 Mosby, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6094=[""].join("\n");
var outline_f5_60_6094=null;
var title_f5_60_6095="Paracentric inversion";
var content_f5_60_6095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paracentric inversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 275px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAETAZgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK53x74g/4RnQBqAkhj/0mCDdLG0i/vJFTGFIOfm4PasN/ir4fTxANJMOq7/7U/sZrr7G32dbvjEZk6ZORj8zgc0Ad9RXB2nxU8NXdotxbyXTD7DdajIhhIaGK3YrJ5gP3TuBAB61m+IPiBrvhz4Rw+L9R0GK7u5I0uJLW3mEaWschGzeznLEBlB2g8npgZoA9Ooryn4l/FG+8I6no9tb6XZvbXtobmW8vLiSKGA5ACsyRvjOepxXTXXii8sfFfhmzuorSTStdgdIp4GLGK5VPMCls4ZGQPtIAOV96AOworznTfiTGPDlx4i1eArpd3qbafo1taRNJc3eHaMHGcFnZHIHGFHU5qv4q+K8Wn+ANW8TaHo15qC6ZdvZXUM7Lbm3kQhW37jkgMwHygnJ9MmgD06ivLfif8Tr3wdc6FHbaXazQajbyTzXV3PJHDbbduAzJG553YyRV/WPixoWiQt/aK3Vw9tYw3t9Np0RuLe1WUDZmTjIY/dwORzxQB6HRXnni3xnr3hzxvoVhLpOn3Gi6vfx6fA0V0xvMlNzzGPbtEaHOfmJwM8ZFRWPxNXUfiuvhKw08yWHkzH+0zJhXmiwJERcfMFJ2ls/eDDtQB6RRXLeBvEN3rEmt6fq8MMOraPfNaTiAERyIVEkUigkkBkdTgk4INdTQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUEgAknAHNFeH/tZXHii38Ax/wDCPiQaM7MuryQgeYsWV247hc5zj2zxmgCbW/jxDba9FY6F4X1DXbW7DtYXtpKBHeCMZmKZHRMEH6emKzLX9oee8WzNn4C1mb7bDJcWm2ZP30cefMYcdFwa858zyVhPgxr6SO3jA8Ell5kiZT/aRYHqR83Xkc4oV0iKjwqb5oIQyeGMjO/TW3fb2OepB3ct83pQB9K/DLx9pHxC8OpqmjuVdcJcWzZ327/3WOBn6jiuur5a+DxaD45aXBpYePwi2kztohUBRPBu5aTHJbfvB388D2r6loAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMPxj4as/FmjDTNRkuIoPPhuN0DKG3RuHUcgjGVGeOnpWG3w00dvMzc6h+88Qr4lP7xP+PlduE+5/q/lHHX/aruKKAODsfhZ4esrzxddQfazJ4mikgug7grCkm8usQx8oZnZiCTzVe48A3niT4ZWXhTxfqk0BhjWC4l0mRQLqOPhC3mxnaThWIHQjqRXolFAHBa98NYdd0m203UPE/ic2cdv9lnjjuo41u49xOJQI8ZwduVC5AAOat3vhSe58XeGJo/s1v4d8Pwu9tAjsZJJzH5SAgjARELYO4kk9BjnsqKAPNNN+GrN4bfw9qt20dhp2rHUtEvbGXbc24LtIoYMhXcpd1/iDKegqjp/wkkuvB3iHw54g1q9Sz1PWrnUTJYyoZJ4ZGDIspeIjdkAnaByODivWaKAOF174cx63ottpd54o8Trax27Ws4huo4/tcbHlZQI9p4O3KhTjg1znxE+Ddvq/h3VbfwneT6Xd3dhbWH2Zp9tpMkBAi835GfKrkAg+mc167RQBwV/8M7W78enxaPEHiCHUcIixRzxeSkYwTEoaMsqMRkgMM5PNOi+FXhO38a2Xiiy0yK11C1V9scKIsTuxz5jDbkuOcHPeu7ooA5TwJ4evtIm17Utakt31bWb43Uy27M8cUaqscUaswUthEXJIHJPGMV1dFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTZY0ljeOVVeNwVZWGQQeoNOoJwMnpQB8zfEvwVovgjX9Jn/4T2+8MWUQnXRrKDSpLtbUSD9+AwJ+9uPB5GeOlcXpll4Xt5dKt9N+Luqwy2iSWWng+HJsRLMSHTkc7ixr6K8cSPr0ti3hz4k2fh4RFxKsS29x55/4E3BXB6eprm7fSNeS5t3f43RSxq4dozZ2g8xQeRkN+GaAOy+FHw70r4ceHRp2mZluZSHu7psgzuBjdgk7RjsK7Wqun6jZalG0mnXltdxqdrNBKsgB9Mg1aoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikZ1UHJAxQAtFAIIBByDRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXGRfEnw3L4+k8ILdsdVQYDBcxNJyTEGH8YAye3bOQRXOfHv4lp4H0L7DpsqnxBfIRCBgmBOhlI/ML6nPoayv2d/hm/hyw/4STxBGx16/XciS8tbxtzznne3U9wOOuaAPa6KKKACiiigAryb49+IfE9oNA8L+CfLh1jxDJLGl0ZNjwrEFdtp6AkZGfTpzgj1mvIf2lfCl3rXg6HW9COpf8JBocnnWSWIyzh2RZAQOcbcnj0PXNAHz/deEtE8QtfSeHNECL4pKS+GzJIQYltM/bd/pu2tgc/hT7nwnoGs/bJNC0JYotekXUdE3uR5VnbbhdK3PyklTgc59emb3xAew0G11a60CWzubS4e0XS7nSpjJHoOcC5SXH+rMpJ478/SrvxEtY/C6m7sIkbRNWurY6FqthIxtNPtScTws38AfJyo64PuKAJfh34kt/AHxTtLy3F3YeA/FitLp1lF+8AYsI1LqTlSGz0J6jqOn13XzH8KPCFr4l+NGu6vAdNvvCPh+VrPT7fcZY4mIDKYV5XAOTnPU8V9OUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFRXU621u8z/dQZNef6l45hFw6CRcKeAO36UAdX4n1CaysHNrgSYPzd14rxC7+Jl5YasYJmmmkJxvxnNdrL4tgv08iRlBfj/PFJpPgSw1C5W8cBiem3p/OgDqPBWrzalBFM6HEi9D29662qemWEOn2yRQqBgYJ9auUAFFFFABRRRQAUUUUAFFFFABVLVr1bGzklY42jNXa5/xSgurWa34LFcAfUf8A16AOT0b4mafqWuyafDMTcoQGDDA644r0mCUTRK69CM14N4P+Fx03xRJqjuWBfd8x56/WvdLCMx2qKewoAsUUUUAFcz8RfGNh4H8MXGr6gQzL8lvADhppSDtQflknsATW7qd/a6Xp1zf6hMkFpbxmWWRzwqgZJr5ZgTU/j98TTLKJrbwrppxjp5cRPT08yTHPoB32jIBq/BPwdf8AxB8V3HxB8Zjzrfzi9rG4+WaRTgYB/wCWaYAA7kexz9NVBYWdvp9jb2djCkFrbosUUSDCooGAB+FT0AFFFFABRRRQAVxHxd8U3vhvwtIvh1ba58T3ZEem2Eo3NctuXzNqAgttQlvTgZrt6+d/2sdevPCmp+A/EOleV/aFjcXXlGZNyfMiA5HfigDR8EfBvVPC3iLV7W2uNLvfAetxqb6x1BGe63BTwMLt4ZjglvwyM1Y8HfCHWfDmo6toE1/p+qfDa/DEWF8XkuYWI42fLtUg989gcZ5rwv8A4aX+IH/PxpH/AIBn/Gj/AIaX+IH/AD8aR/4Bn/GgD3L4Q6Na/Cvx9qXgUyyXS6zu1SwlXB8qFMrslJx83HUAg47V7jXwp/wufxX4017w7p+qy2Mf/E0tyLmzhMM4UuAUD5+6c8jvxX3XQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBDevLHZzvbrvmWNii4zlscD86+Xh8Svj0Rx4JXv10uX1/36+p6KAPlj/hZXx7/6Elf/AAVy/wDxdH/Cyvj3/wBCSv8A4K5f/i6+p6KAPln/AIWV8eRy/goBfVdKlJ/LfX0p4auNQuvD+n3GtW0drqMsCvPDGxYI5HI5AOfUdjxk4ydKigDM8TIZPD+oBThhCzA+4Ga+KNX1q/sdauVdt2xm/UmvuDVHSPTLtpf9WImLfTBr510vwpa65qVxcMqYdj1oA8M0/wAQ61deIbdIVkKFsE44619t/DaGdfDVq90P3uwA15PpnhDTbHXUxGudwIr3zT0SOziWIAJjgCgCxRRRQAUUUUAFFFFABRRRQAUUUUAFZOsW5M8U6g4HDVrUjAMCGGQe1AFO32+WuOlWUlRsBfpXmPj3xHd+G7p1jR2iJ4YdhzXL6b8VsZnYgAeo4oA96qMzRhiu4ZHB9q+b/Fvx8eC3eGwhYyspwBycivPvC/xQ8V3fiGKe7Dx2rcsSOP5UAfaFzBDd20kFzFHNbyqUeORQyup6gg9RWb4Y8N6T4W002Gg2UdnaGRpSiZOWY8kk8nsPYADoKqeENcXV9Pjl3KSwySK6KgAooooAKKKKACiiigAryL4tRxy/F/4TJMiOhur7KuAQf3K44PHXpXrtfMv7bTtFpvhGSN2jdbifDqdpHyp0PagD6IOkaPk50/T8+8Cf4Un9kaN/0D9P/wC/Cf4V+Z/9oXf/AD/3X/f4/wCNH2+7/wCf+5/7/H/GgD7c/aMsbG28J+Hns7W1hf8A4SGyAaKNVPVuhAr2evzT8HXU83jLw6k11NMo1O2O15Cwz5g5xX6WUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYnjS5W28L6i7fxRMg9yRivBfDmrPppdVB+UnnPrXsnxRcf8I55JbBlf19BXluheGnu4mcfMDn9KAMuz1uS68Sx5Y8Ngc+tfRmkf8gy25ydgya+abvTzpfiKH3bP5Gvo3wzK02i20jdStAGpRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO+LfDlvr0GydcnbjP515HrXwiZi/wBmOM5wVHH8q9+pNo9B+VAHyXefCS40mcz3MRZc7skZz+lakum2kGkssdugYck4719Ia3bxzWMiuikY7ivHLm1tDeTW5K+m3igDN+DviVhqTWMrH5T93068V9CRksgJ6183+HNOtbLxeohkUOewOK+jLP8A49k5zQBNRRRQAUUUUAFFFFABXi3xy0mx1/4k/C7SdXt1utOurq986BiQr7YkIzjnrXtNeS/FX/ksXwk/6+r/AP8ARKUAaX/Cjvhv/wBCraf9/Zf/AIqj/hR3w3/6FW0/7+y//FV6RRQB86fGr4b+EfCGjeHdS8OaJBYXw16zTzkdydpYkjljxwK+i68i/aY/5FDw9/2MNl/Nq9doAKoxavpst+9jFqFm96jbWt1nUyKcZwVzkHHNVNY8PW+q6hZ3k15qsElqQVjtNQmgjfBz86IwV/8AgQPHFeNeHvAOueFviP4FjnsbO7sba/1aeTVbSORpZFmhkKtdMVAVssFHzEHFAHqGk/EXwxrGka9qml6kt3p+iK73k8SMyqFQuSpx8/yg9M1a8F+MtK8Y280+irf+RGsbiS5s5YFkVwSpQuoDjA6jPUeorh/DPgrxbay+PjrFt4aki8SiSVYlu55UWQoE8tx5aHyypbLA5HGB3rS+EPgXVPCN7rt1qT6da29+0Qt9K0yWWS2tgikFgZcHc2RkAAcd+wB6VRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4/+0ZrLaNounzBsDc5PP0ry/wr8UAlgY/mJUc8f/Xr1r4/6Cuv6NY2zAHLMOfoK5TwN8I7ZtNBkJG4EYHTtQB5Tf8AjZ9a8WRwRDDeaoHPv9a+v/CYK6FbKRyBXgdz8KrbRvFMF2qL8rZJP14r6D0CPy9NiHtQBo0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV5v4u+MGg+GfE91oM+na7f6haxpLMNPsvOVFcAjJ3D1H51k/8L70H/oXPGH/gqP8A8VQB6lqzbdPmOM/Ka+LPGXjG+sfGl3DblwgcgDn5vevq3wR420/x/ZaibDT9XsltWEbjULXyS+4E/Lyc9Oa8i8X/AA8tm8Wm6kjGWJwcdB6UAeIaF4r1YeN7Z5wxjLgnOR2PFfdXhu8+26RbyHqVz9K8NuPh3YrcQ3EUa7lPGB3r0TVPFtl4C8NWd3fWOp3sU0ggVNPt/OcNycsMjA96APQqK8h/4X3oP/QueMP/AAVH/wCKqO4/aC8NWtu1xeaJ4rtrZCA802mbUTJwMndxQB7FRUdtOlzbRTxZMcqB1zxwRkVJQAUUUUAFfN37Y+o3mjDwXqWlXMlpf29zcGK4iOHTKoDivpGvnb9rXS49cv8AwLpU+o2mlxXNzcA3t422GHCIfmPbPQUAfOf/AAtb4gf9DhrH/f8ANH/C1viB/wBDhrH/AH/NdL/wp/S+/wAUvBX/AIFij/hT+l/9FS8Ff+BYoAwdK8ceKfEniXw5Ya/r1/qNmNVtpBDPIWXcJAAf1P51+h1fBL+ALPwxq/h7UrXxr4c11/7XtY/smnXAeXBcHdj04x+Nfe1ABRRRQAUUUUAFFFFABRRRQAUydzHDJIqNIyqWCL1bA6Cn0UAjhP8AhOtV/wChI1//AL5T/Gj/AITrVf8AoSNf/wC+U/xru6Kx9nP+f8Eel9bwv/QOv/Apf5nCf8J1qv8A0JGv/wDfKf40g8dat38D6/8A98p/jXeUUezn/P8Agg+t4X/oHX/gUv8AM8U+KnjTWZvCUixaDrmiOJoyLx2EYXB6ZU55rzvRvi74v0zarX6X0Y/gu4g//jww3619N+I9C0/xHppsNXhM9oXV2QOyZIORyCDUOjeFdB0XadL0iytnXpIsQL/99Hn9a5KuFrTqc0Z2R9Bgc+yyhg3Rq4VSldu266dXdr5I4fwZ8R9f1vYLnwXqDI3/AC8Wx2ofp5m0f+PV6hGxeNWZGQkZKtjI9jjIp1FdtOEoK0pXPmsbiKNefNQpKmuybf5v8kjhPijP5VnG+M+WMj61z/hzxqllabJCBtHFZ3x+8QnTmhthgbgP5V5hoguNTtd0ectnrWhxHeeIfiBb3mtJEHyWYY/ziva/DVwLrR4ZR0I4r4i8W6NfaRrEF67PhGHTAHJr6w+DesrqXheBc8xgLn1oA9BooooAKKKKACiiigAooooAKKKKACiiigDyLwOT/wANF/Eodvsmnf8AooV67XkXgf8A5OM+JX/Xnp3/AKKFeu0AFeP/ABT1dLG7jPUk4GOtesX03kwFs4rwnxfbHXtfOCdqnAGe1AEUvjBYrWIEjOeR6n8q9j8DT/bNBiuicmT+lfOfizRmtp7eCME5OAF/nX0V8P7U2fhOxiYHO0nn60AdFXmf7Sv/ACRDxR/1yi/9Hx16ZXmf7Sv/ACRDxT/1yi/9Hx0Ad54c/wCRe0v/AK9Yv/QBWhWf4d/5F/TP+vWL/wBAFaFABRRRQAV8x/tvDOk+Ex/08T/+gpX05XiPx90Ow8T/ABB+GWh6yjS6beXN4Jo1coW2xIR8w5HPpQB8R7V/uj8qNq/3R+Vfcv8Awzb8OT/zD77/AMDX/wAaP+Gbfhz/AM+F9/4GvQB8Z+CVA8a+HTgD/iZW3P8A20Wv0xr5i+LHwi8JeA9O8Pav4ctLmK/Gu2cW+S5aQbSxJGDx/CPevp2gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDxr4/wCkxXcMMzhd2wAEj0JrhPBFzb2MWGx/SvVPjZbtPp9kEOMlgePp/jXnOi+FZJbcOuc9etAGH8Ur2HUrZEhxuwc49ea9L/Z9tJbTQYElJJK5b61wHibwzNAgYjPOelerfB87NNCnrnjHpQB6ZRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkXgf/k4z4lf9eenf+ihXrteReB/+TjPiV/156d/6KFeu0AZHic7NNkfJwAeK8U8NX3neIbgO2SGPHoPSvafFmRotyVAJ2GvkrQvELp4xvYY2JKyYPuaAPVNXSC78S2sQZdzMBg+h617xFGsUSRoMIgCgewr4m1vxbdWfjuwNwWRBMv4t6V9rWsontoplOVkQMPxGaAJa8z/AGlf+SIeKf8ArlF/6Pjr0yvM/wBpX/kiHin/AK5Rf+j46AO88O/8i/pn/XrF/wCgCtCs/wAO/wDIv6Z/16xf+gCtCgAooooAK+dv2ttI1HxBfeBdI0JDJq11c3It1DhCSqIT8xIAwPevomvIvizKkXxf+EryusaC6vss5wBmFMcmgD5sPwN+K4JH9nT8f9RCP/4uk/4Ud8V/+gdP/wCDCP8A+Lr7h/tvSv8AoJ2P/gQn+NH9t6T/ANBOx/8AAhP8aAPhlvhr458I6v4d1TxXayQ6aNXtYstdpLhy4I+UMT0B5r72rxn9o7ULK78KeHktLy2nf/hIbLCxyqxPLdga9moAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiqmp6jZaVbfadSuobS33BfNmcIoJ6ZJ4FS2tzBdwia1niniPR4nDKfxFK6vYrkly89tO5NRRRTJOH+KcYfTICx4BP9K4zw7rESKE4J6V6D8QrdZtKBbtmvL9N0horhm3HGeKANnxXdxPaZO3HTP1rpPhqIvskaxdAP1rz3xWjPCsSNya734V2kkGmq8m4lzkE+lAHoVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeReB/wDk4z4lf9eenf8AooV67XjXhW+tLD9on4kNf3dvbK1np5UzSKm7EQzjJ5r0/wD4SXQv+g1pn/gVH/jQAeKI/N0W5XB5Qj9K+QtO0w2fjW6kmXYpc7eO1fX2pX9rLpDTwzxT28ikpJG4ZWHqCODXz/caAb7Xp5YOdzcketAHjPxImQeK7JrZQWDYHHRcda+3vA1x9q8JaXLnOYFBP04r5n1T4em88QWzzD7rAnjOR6dK+ltGms9C0K1TULq3s4QAiNPIqA+gyT1oA368z/aV/wCSIeKf+uUX/o+Ou2/4SXQv+g1pn/gVH/jXnH7Ret6Td/BXxPFa6pYTStHEFSO4RiT5ycAA+1AHpvh3/kX9M/69Yv8A0AVoVn+Hf+Rf0z/r1i/9AFaFABRRRQAV8x/tv4/snwpnp9on/wDQUr6crxv406fZ6t8UfhXYapbRXdjPdXvm28yho32xIRkHrg0AfC22P2/OjbH7fnX6L/8ACp/AP/QoaL/4CrR/wqfwD/0KGi/+Aq0AfAXggIPG3h3bjP8AaVt0P/TRa/TOvAPjr4I8MeGvD/h690DQdO0+8/t+zXzreAI+CxyMjtwOK9/oAKKKKACiiigAooooAKKKKACmTiQwyCEqspU7CwyAccZp9FAJ2OE+wfEX/oM6B/4Cv/jR9g+Iv/QZ0D/wFf8Axru6Kx9gu7+9npf2nP8A59w/8Aj/AJHCfYPiL/0GdA/8BX/xo+wfEX/oM6B/4Cv/AI13dFHsF3f3sP7Tn/z7h/4BH/I8N+MVr4wi8EzNr2o6TcWPnR5S2gZHznjk15d4W8M+MbmZZvD1hqsLN0niLQKf+BkgfrX2CyK+Nyg4ORkZwfWnVy1cvVSfO5P+vM93A8XVMFhXh4UYttt7WXT7Kt+Z5b4M0b4m23lnV9d08W//ADyuY/tLj6ldpP8A33XqEe8RqJGVnx8xUYBPsMnH506iuylSVNWTb9WfO43HSxk+eUYx/wAMUvy/U4/4izGK0thnhic/pWBo0Udzabsgkg55q38bmlg8Ki6gBJjbaT6Z/wD1V5V4P8STeUQTn05rQ4jV8Vs1rqSbj8mcHj1r2DwRtbSINuMqvNfOHj/WLh7iN9rEE5J+ma9s+Duotd6DB5vEjqCQKAPR6KKKACiiigAooooAKKKKACiiigAooooA4zxP8L/BninVn1PXtBtry/dVRpmd1LBRgZ2sB0rJb4HfDfBz4Wtcf9dZf/i69JpsrbI3b0BNAHiHxC1XTvBPh230XQ7ZbSwtwYreBGLbdxJJyck888nvUXw/mP2H7RcnJ/iJ7nNYPj7T5td8ZAKWMUTFVXsevNamurLouiiKIENt28d6ANaLVIrzxFFDCoclwuB3Nej+JvBeheLNLtrDxPp8eoW8EnmojsyhX55BUg9yK80+CehT3N++q3i4SE/IezHnBr26gDzf/hR3w3/6FW0/7+y//FUL8D/hwrBh4VtMg55klI/LdXpFFADIY0hiSKJQsaKFVR0AHQU+iigAooooAK8l+Kv/ACWL4Sf9fV//AOiUr1qvnn9q7X7zwnqvgPxBpYhN/Y3NyYhMpaM7kQHIBHb3oA+hqK+If+GmfiD6aL/4Ct/8VR/w0z8QfTRf/AVv/iqAPoH9pj/kUPD3/Yw2X82r12vhW9+Mfinx/qfh7RfEC6d9jOr2s3+jwFH3BwAMljxya+6qAMbWbvXYNQs49J0iyvbNyPtE81+YHiGedqCJt/HPVfT3rx3wd8TNd1Hx14fstT1S0X+0L7Uob/SBahH05LeOQxqX6kttDEnrnive6zdQ0LTtQ1jStVvLfzL/AEtpWs5d7DyjImx+AcHKnHIOO1AHgHw08SWD+L/Ft78PL271G3i0wxWWjXl/JNLqN0jgm6PmMdi8heoJBJwOBXRfs46jrc+r+NrHxA+sXF1Beozy37JiNymWQKrsE5JIVcqBjnNe30UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGL4y05dV8O3do4yHA/nXhS+FDpt6VTJAPevom9BNpNt6hCR9a8A1PxZAuqSLO4BViMGgBNe8PC5sfu5biut+FMDW0XlA4KnjNcdqXjmyisThl4GeTmuR8HfFBj4p+yQozKX2ggcUAfXA6CiqOi3Ju9PjlPXpV6gAooooAKKKKACiiigAooooAKKKKACs7xDexWGkXE87bUVTz+FaNcV8YdL1DV/A17baUjST/eKL95gAeB+dAHnPh7xHYX+uSzsVKhjt9cZNaGoXlp4g1iGwtSrs52gH0r5wDan4et7nzYpY5yT8pBBHXPGK9g/ZY0fUtUvbrxBqgIt4ztgJXGTzQB9HaRp8Ol6fDaWygJGMfU+tXKKKACiiigAooooAKKKKACvmP8Abe/5BXhP1+0T/wDoKV9OV5J8V1VvjD8JQyhgbq+4IyOIVxxQB8Ibh7/kaNw9/wAjX6gHTbEnJs7bP/XJf8KT+zbH/nytv+/S/wCFAH5s+CT/AMVr4dODxqVt2/6aLX6Y145+0ja29v4R8PGCCKM/8JDZfcQDu1ex0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABAIIPQ18ufE34aaxceIZzp7ny3clQFxxn1r6jpkkUcmPMRWx0yKAPljRPg9qclqEvWdGIx83NdR4N+CMOm6ul5MCzqfvAYFfQCoqjCqBj0FOoAitIFtreOFPuoMVLRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBieIPC2i+II9urafBOf75XDfnV/SNMs9H0+Gx02BLe1iGFRBgCrlFABRRRQAUUUUAFFFFABRRRQAV4l8etbsfDPxC+GOt6zK0Gm2d1eedKqFyu6JQPlHJ59K9trxH9pvwgfEtt4dvL43Efh7TJZZNSls0MlzGrhFQxx4O4Z6+g5wcUAXf+Gjvhv/0Fbr/wCl/+Jo/4aO+G/wD0Fbv/AMApf8K8rX4C/DxlDD4mQAHnBuLcEfX5qd/woT4e/wDRTbf/AMCLf/4qgDZ+Lfxa8IeO9M8PaR4cv5p7/wDt2zl8t7Z4xtDEE5YAdWHvX01Xx9oHwZ0WP4vaBYaD4huNW0uKH+0J763VJUjmjfKxllJVc4HXmvsGgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqrqoiOmXguUneAwv5iwb/MZdpyE2fNux02856c0AStcQrG8jTRiNDtZiwwp9CexpYJ4p0LQSpKoOMowIz+FfNnhvQxe/Bnxr4Z1LRvFlnb3GtNcxhNKne4a3aeNkZBIAZDiP5uSwHJB7+k/s/wBjqFh4T1GK/wBGTSoG1GVrQGwWxlnhwoWSWFeEY4x2OFHHcgHp1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQSXltHdxWklxCt1KrPHCzgO4HUhepAyM/Wp68x+JTeII/GFhJocF68CaJqZMlvblwtxsXyRuAOGJzgZ596APTqiu7mCytpLi8nit7eMbnllcKqj1JPAFeBWen/EMWzQ22r+JWur7wfHqJe7TiDVFeM+Qp2AISNylDzgknJGaffXOvav4P0rV/HEN5Z6dqniu2a5067QotpZKSsaSKw4VpljY56hhQB72s8LLEyyxlZRmMhh84xnj14pv2u287yftEPm5xs3jdn6V478U4PJ+MfgTVrbSNfu/sLym9ntbO5uII42jKx4CgoG3E5wM4xnjFYCeG7m2+O66lo+hajdyXWqvLfz6lo6pBbxBceZBdZ5PoB1zyB0oA9/s721vkkeyuYLhI3aJ2ikDhXHVTjoR3FWK888GBU+Lfj5NP4sDHYvcAfcF4UffjtuMYi3fhmvQ6ACiiigAooooAKDRRQBwTfB/wCHzMxbwnpZJJJJjPU/jR/wp34e/wDQpaX/AN+z/jXe0UAYnhbwroXhS3ng8OaZb6dDO/mSJAuAzYxk/hW3RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVX1CytdRs5rPULaC7tJl2yQTxiRHHoyngj61YooAbGiRRrHGqoigKqqMAAdABTqKKAKun6dZackyafZ21qs0rTyCCJYw8jfedsDlj3J5NWqKKACiiigAooooAKKKwZfGPhyLxAuhya1YrqzMEFr5o37j0XHZj6daAN6iiq+oX1pp1o91qF1Ba2yEBpp5AiKSQBkngZJAHuRQBYooooAKKKKACiiq2o3sGnWM15eOUt4V3OyozkD6AEn8BQBZoqhqmsWGlWsFzqFwIIZ5Y4I2ZT8zucKvA7k1foAKKhvLq3srWW5vJ4re2iUvJLK4REUdSSeAPeqVxr2mWzyie7RFitPtzyEHyxBk/Pvxtxwe+e9AGnRWPoPiXSteI/sq5ecGMTAmGRAUJIBBZR3BrYoAKKy7PxBpd7o0+q2t2smnweb5kwVgF8skPxjPBU/lVzTr231LT7W+spBLa3MSzQyAEB0YAqeeeQRQBYooqjomrWOuabFqGlXC3NnKWVJFBAJVirdQDwykfhQBeoopssiRRvJK6pGgLMzHAUDqSewoAdRVPR9TtNZ0y31DTZTNZzrvik2Mu9fUBgDj0PerlABRVGy1axvdQvrG2nDXliVW4hKlWj3DKnBHIIzgjg4q9QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeVeDNG8R+GL3UtHk8OwX1pd6rJerrP2mIAK7bg7xt85kX2GM9+9eq0UAfPWk+A/Glpp+sJNDqLatNptzbPcLfRGG8lblHyX37s9CyrjkZxVnxJ8Mdam07XLPTLGeSC50+wlWOXUCwlvY5QZeWc/MUyMn5cnr3HvlFAXPJ9N8Garcaz4mvRBfaSG0+2j0QSaizrbTfZ5EYsqSEMVZl5bPcgnrWDZ+C/FkfhnxBBY6fc6bJPo0Notq2oLI11fKxL3CtvITI4ySCe4Fe7UUAeGS/DrW7TW7y50u1vVig1XTrmxJ1IsAmxftbYaTklgc7uT2yKgTwP4wi8Q6rdTJfzXchvtl7DeRCKeOSNxGjBn3jBKALtwpGQRXvVFAHiOufD/AF4eEfCUFnDeXLRRB9bsWvzI8s5gRQwMkmwhGVvlDBecjpXUX2g663wSn0S2F7Jrv2MwxCe4Tzs7vlDSBtuduOc/ia9GooA8K8Q+CfEl74mkuJtIm1CQ6nYXNvqBvYwlvax7N8Xls4IIIY8A565zS6f4K8W2/i29vbtL+adpbwi+iu4hFPFIjiNXDPv4yoC7cKRkGvdKKAPAX+GWvNoi2yWtwJr3wy9vfiXUC6vfBkaMHLnuDyPlxx0q3e+B9fvtGvrOLRrq1tJPCv2KKzkv0f8A01bh3xkSEc/K2c4wdpPBFe50UAeMaj4J8UJZ6tZ6AZbKOTQLW1tmN5x56yl5kB3EqSpK7unzdeKy7TwR4kh0+GNtJ1OXShqUVzc6M99BH5qCNlPllZCoUNsYqzDcewr3uigDzXwV4a1bTvhBqmi3dj9n1KdL4RW3nI/+saQoNwJHIYd/rXF6Z4I1q18Nas19b3Hhyzg8NR20pe+EhmvYcOLgbHbaq7CvUHBxjFe/UUAcB8Fo9SufCR17XXZtS1yY3zKSdscZAEaqOw2gN/wKuC8F+CPFemf2d5OjNp91ZWupLcyz36tFfmUuYItsbkqoZlYn5cYOOTXvlFAHznpvgTxtHY6nDHp17ZR3aWLNCl7DGBKk4MpTZIcAJnBJyR3zxXrXjnQZI/hZrmjeHknMhsZkhRpXlkfIJK7nJYk5I5PeuyooA8zi8Haf4ytrbXtH8YeLNP0+8giMNppmp+VbwqqBNqptO0jbyP72ad/wqf8A6n74gf8Ag5/+wr0qigDgdM2XfxjvJbBjLBp+ipZXs2c5naUPGjHuyqHJ9N49a76iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a paracentric inversion, the inverted chromosome segment is located on one side of the centromere (ie, on one chromosome arm).&nbsp;A representation of normal chromosome 15 is shown on the left. An example of a GTG stained chromosome 15&nbsp;from a patient with a paracentric inversion of the long arm of chromosome 15 between bands q15 and q24 is shown on the right.&nbsp;A normal GTG stained chromosome 15 is shown in the center. The red arrows show the&nbsp;locations on the normal chromosome where breaks occured in the abnormal chromosome (corresponding to the boxed area).",
"    <div class=\"footnotes\">",
"     GTG: G-banding with trypsin and Giemsa",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_60_6095=[""].join("\n");
var outline_f5_60_6095=null;
